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Roles of endothelin 1 in follicular and luteal function 
Fernando P. Perea-Ganchou., M.S. 
 
Reproductive activity in mammals is characterized by the recurrent presence of follicles and 
corpora lutea (CL) in the ovaries. In addition to the roles of follicles and corpora lutea in 
regulating the activity of the hypothalamic–hypophyseal–ovarian axis, those ovarian structures 
are responsible to generate a viable female gamete and to provide the appropriate uterine 
physiological conditions to sustain the embryo/fetus development during pregnancy. If 
fertilization of the oocyte does not occur or pregnancy fails, a new ovarian cycle starts a few 
days later, assuring further opportunity for onset of a new gestation. Numerous locally 
produced ovarian factors modulate function of follicles and CL. Endothelin 1, a 21-amino acid 
peptide produced in the ovary, modulates steroid production by granulosal cells and mediates 
luteolytic actions of PGF2 . Three experiments were carried out in order to examine the role of 
endothelin in follicular steroid secretion in vitro and in spontaneous and PGF2 -induced 
luteolysis in sheep. 
In experiment 1, it was hypothesized that endothelin 1 (END1) acting through its receptors 
ENDRA and/or ENDRB, on granulosal cells of ovine preovulatory follicles would inhibit 
steroid production, and therefore, prevent the premature luteinization of granulosal cells of 
those follicles. On day 14 of the estrous cycle (standing estrus = day 0), 17 nonpregnant Suffolk 
ewes were injected with 2 doses of PGF2  (5 mg) 3 h apart. Thirty six to 40 hours after the 
second dose of PGF2 , ovaries were removed by mid-ventral laparotomy. The 2 or 3 largest 
follicles in the ovaries were dissected and granulosal cells were harvested under sterile 
conditions. Aliquots of 15 L of granulosal cell suspension from each presumed preovulatory 
follicle were cultured in 96-well plates containing a solution of 185 L of Ham’s F12 
supplemented medium  and treatments (single and combined effects of LH, END1, ENDRA 
and ENDRB). Data from estrogen-inactive 20 follicles collected from 13 ewes were analyzed. 
Accumulation of E2 and P4 by cultured granulosal cells was not affected by either LH or END1 
or the END receptor blockers. Granulosal cells from follicles with the greatest concentration of 
E2 in FF produced on the average significantly more E2 and P4 than follicles with lower 
concentrations of E2 in FF. In conclusion, END1 did not affect steroid production by granulosal 
cells from preovulatory follicles in sheep, and therefore the working hypothesis was not 
supported.  
In the second experiment, the ENDRA antagonist BQ-610 was delivered into the CL via an 
osmotic minipump to examine the expression of genes related with P4 production and 
structural luteolysis at 6 and 24 h after exogenous PGF2 . It was hypothesized that sustained 
blockade of ENDRA would prevent upregulation of genes stimulated by PGF2  during 
structural luteolysis. Minipumps loaded with either vehicle (2:1 methanol/saline solution) or 
2.5 mg of BQ-610, were implanted in the mesovarium, with a catheter into a CL, on day 7.5 to 
9 of the estrous cycle. A dose of PGF2  (25 mg) or saline was injected 48 h after surgery in all 
animals, respectively. Six or 24 h later ewes were euthanized, ovaries were collected and CL 
were dissected and stored for later determinations of hormones and gene expression. Data for 




that in 9 of 10 treated ewes, BQ-610 did not prevent luteolysis, and the pattern of gene 
expression confirmed this finding. Exogenous PGF2  downregulated expression of StAR, 
3 HSD, VEGF, TIMP-1 and eNOS (P ≤ 0.02), whereas it upregulated 20 HSD, MMP-14 Bcl-
2 (P ≤ 0.03). Expression of Bcl-2 and Bax were reduced and Fas-R was increased from 6 to 24 
h after PGF2 . In BQ-610-treated ewes, mRNA expression was upregulated more for 20 HSD, 
and caspases 3 and 8 than in vehicle-treated and control ewes. In conclusion, PGF2  induced 
luteolysis in both vehicle-treated and BQ-610-treated ewes. Given that in BQ-610-treated ewes, 
certain genes related with P4 metabolism and apoptosis were differentially upregulated, the 
greater dosage of BQ-610 used in this study, or its combination with methanol may have 
activated ENDRA. If so, these findings would confirm that END1 via ENDRA in luteal cells is 
associated with structural luteolysis as previously reported.  
In the third experiment, it was hypothesized that chronic delivery of BQ-610 into the CL 
would prevent luteal regression induced by endogenous PGF2 , thereby increasing length of the 
estrous cycle and maintaining functional and structural characteristics of the CL. Ewes were 
assigned receive an osmotic mini-pump containing 2 mg of BQ-610 (n = 12) or vehicle (n = 9), 
implanted surgically on d 9 of the estrous cycle. Corpora lutea were collected 12 h after onset 
of estrus, or on the afternoon of d 21 in ewes that had not returned to estrus, and from untreated 
ewes on d 10 to 12 of the estrous cycle (mid-phase CL). Three of 12 BQ-610-treated ewes did 
not show estrus before d 21 compared to 0 of 9 vehicle-treated ewes (P = 0.33); CL of the 
remaining nine ewes treated with BQ-610 were excluded from further analysis. Estrous cycles 
in vehicle-treated ewes averaged 15.5 ± 0.2 d. In the three BQ-610-treated ewes, luteal weights 
on d 21were greater than in vehicle-treated ewes on the day of estrus (0.62 ± 0.05 versus 0.39 ± 
0.03 g, respectively; P < 0.001), as were luteal contents of P4 (20.9 ± 1.8 versus 1.3 ± 1.0 g/g, 
respectively; P < 0.0001). Serum concentrations of P4 in the three BQ-610-treated ewes 
remained above 1.5 ng/ml through d 21 (P < 0.01). Their luteal tissue appeared normal with 
53.3 ± 5.8% of apoptotic cells, whereas luteal tissue in vehicle-treated ewes was markedly 
disorganized and in an advanced stage of structural regression. Expression of mRNA was lower 
[3 HDS (P < 0.01), and TIMP-1 (P < 0.01)]; greater [preproEND1 (P < 0.01), END receptor A 
(P < 0.01)]; or similar (Bax, Bcl-2, Fas-R) in CL from vehicle-treated than in CL of BQ-610-
treated ewes or in mid-phase CL. Caspase 3 expression was grater in CL of vehicle-treated an 
BQ-610-treated ewes than mid-phase CL. In conclusion, chronic infusion of BQ-610 blocked 
luteolysis and lengthened the estrous cycle in 3 of 12 ewes. Furthermore, functional features of 
CL of those 3 ewes were similar to mid-phase CL. Overall, these results supported a role for 
END1 in luteal regression in sheep. 
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REVIEW OF LITERATURE 
Physiologic aspects of follicular growth 
Ovarian follicles are structural and functional entities that play essential physiological roles, 
modulating activity of the hypothalamic–pituitary–ovarian (HPO) axis and providing an 
appropriate metabolic and endocrine milieu to support the development and maturation of the 
oocyte. Eventually they facilitate the release of the oocyte into the oviduct, where fertilization 
takes place. Ovarian follicles develop from primordial follicles throughout different 
morphological stages that are conducive to attainment of the functional competence to ovulate, 
and thus, provide the female gamete required to assure survival of the species. Two follicular 
populations of steroidogenic cells (granulosa and theca) interact with each other to produce 
estradiol and other hormones necessary to modulate reproductive function (Mann et al., 1992). 
Once ovulation occurs, the remnant collapsed follicle gives rise to another essential ovarian 
structure, the corpus luteum. If fertilization of the oocyte does not occur, the corpus luteum 
undergoes functional demise, and a new group of follicles begins to mature a few days later. 
Thus, ovarian follicles are an essential component of reproductive cyclicity. 
Preantral follicular development 
Primordial follicles are the most elemental follicular structures and consist of an oocyte 
surrounded by a single layer of flattened granulosal cells. In domestic animals and primates, 
primordial follicles are formed during the embryonic/fetal period, and most of them will 





newborn human females, only 400,000 follicles remain in the ovary from 6 to 7 million 
follicles present at mid gestation (Gougeon, 1996). The large pool of primordial follicles in the 
ovary constitutes a follicular store from which they are activated progressively and grow 
through different developmental stages. Most primordial follicles are in a resting stage as a 
consequence of local and systemic inhibitory stimuli. Accordingly, in superficial pieces of 
ovarian cortex cultured in serum-free conditions, healthy primordial follicles decreased by 
88%, 90% and 94% after 2, 4  and 7 days in culture, respectively, whereas healthy primary 
follicles increased by 260%, 209% and 197%, respectively, compared with the numbers present 
on d 0 (Wandji et al., 1996a). These findings indicated that certain components of the ovarian 
stroma may exert inhibitory control in the onset of growth of the primordial follicles (Wandji et 
al., 1996a). The initiation of growth of primordial follicles and subsequent development to the 
secondary stages can occur in absence of gonadotropins (Wandji et al., 1997). Moreover, the 
transition from primordial to primary follicular stage is apparently dependent upon 
communication exchanged between the follicle and the adjacent cells, mostly 
stromal/interstitial and endothelial cells, which provide both stimulatory and inhibitory signals 
(Skinner, 2005). Thus, once stimulatory factors prevail over the inhibitory influences, 
primordial follicles start to grow toward subsequent follicular stages (McGee and Hsueh, 2000; 
Durlinger et al., 2002; Kezele et al., 2002; 2003; Holt et al., 2006; McNatty et al, 2007). 
The transition from primordial to primary follicular stage is a process by which a primordial 
follicle increases in size (Wandji et al., 1996a), as granulosal cells proliferate and change in 
morphology from flattened to cuboidal (Lundy et al., 1999). As the follicle develops new layers 





diameter (Lundy et al., 1999). Numerous factors from local or systemic origin modulate growth 
of primary follicles and successive preantral follicular stages (Wandji et al., 1996b; Fortune; 
2003; McNatty et al, 2007). Although FSH did not appear to be essential for development of 
preantral follicles (Halpin et al., 1996; McNatty et al., 1990), evidence indicated the presence 
of FSH receptors in granulosal cells from primary and secondary follicles in ruminants (Wandji 
et al., 1992; Tisdall et al., 1995; Xu et al., 1995a; Bao et al., 1997a). FSH and bFGF stimulated 
a greater increment of the diameter of bovine preantral follicles than EGF (Wandji et al., 
1996b). Moreover, granulosal cells from preantral follicles treated with FSH produced more 
progesterone than control or bFGF- and EGF-treated cells (Wandji et al., 1996b). Thus, it was 
evident that FSH as well as other locally produced factors such as insulin, IGF1, GDF9, 
BMP15, EGF, activin, and steroids, can modulate the rate of preantral follicle development 
(Hulshof et al., 1995; 1997; Gutierrez et al., 2000; Juengel et al., 2002; Souza et al., 2002; Zhao 
et al., 2003). In addition, granulosa-oocyte communication appears to be essential for normal 
preantral follicular development (McGee and Hsueh, 2000). During the development of 
preantral stages, growing oocytes synthesize the zona pellucida, and epithelial cells adjacent to 
the follicle differentiate into thecal cells (Driancourt et al., 1993). Although mRNA for LH 
receptor has been detected after formation of the theca interna, its role in these early stages of 
follicular development has not been elucidated (Bao and Garverick, 1998). 
Antral follicular development 
At the end of the preantral stage, following formation of the theca interna around the 
granulosal cells, thecal cells express mRNA for LH receptor and important steroidogenic 





et al., 1997a; Bao et al., 1997b). Around the beginning of the antral stage, granulosal cells start 
to express mRNA for 450arom (Xu et al., 1995b). Moreover, P450c17 mRNA was identified 
exclusively in thecal cells, while 450arom mRNA was expressed solely in granulosal cells, 
while both cell types expressed mRNA for P450scc and 3 HSD (Xu et al., 1995b; Bao et al., 
1997b). So, it was clear that thecal cells had the capacity to synthesize progestins and 
androstenedione, whereas granulosal cells from antral follicles synthesized progestins and 
estradiol. Therefore, it was suggested that thecal cells under LH stimulus synthesize androgens 
and granulosal cells under FSH influence actively aromatize exogenous androgens to estrogens 
(Fortune and Armstrong, 1978; Fortune, 1986). Furthermore, granulosal cells produced 
considerable amounts of pregnenolone that were used by thecal cells as a precursor of androgen 
production (Fortune, 1986), and androgens produced by the theca interna increased the ability 
of granulosal cells to synthesize pregnenolone (Fortune, 1986).  
Once follicles become progressively gonadotropin-dependent and the metabolic machinery 
is expressed completely in steroidogenic cells, follicles start to form a fluid filled cavity or 
antrum. According to Webb and Campbell (2007), “antrum formation marks the transition from 
a proliferative to a differentiative phenotype for the follicular somatic cells”, which occurs 
concomitant with a manifest increase in the rate of follicular atresia and significant changes in 
gene expression (Webb et al., 2003). At the beginning of the antral stage, follicular fluid is 
synthesized exclusively by thecal cells, and in later stages granulosal cells acquire the 






Although during the antral developmental stage, gonadotropic stimulus is essential for 
normal development of the follicles; other locally produced factors originated from the oocyte 
and somatic cells are important autocrine/paracrine modulators of the follicular growth.  
Several members of BMP family (BMP 2, 4 and 6) increased FSH-stimulated production of 
estradiol and inhibin A by ovine granulosal cells (Souza et al., 2002; Campbell et al., 2006). 
Also, BMP 4, 6 and 7 stimulated estradiol, inhibin A, activin A, and follistatin production by 
granulosal cells without presence of FSH in the culture media (Gliser et al., 2004). Moreover, 
BMP 4, 6 and 7 increased the ability of IGF-I to stimulate secretion of estradiol, inhibin A, 
activin A, and follistatin by granulosal cells (Gliser et al., 2004) and suppressed basal and LH-
stimulated androgen and progesterone production by bovine thecal cells (Gliser et al., 2005). 
Also, GDF9, an oocyte derived factor, stimulated proliferation of granulosal and thecal cells 
and decreased FSH-/IGF-I- and LH-stimulated steroid production in both cell types, 
respectively (Spicer et al., 2006; 2008). The inhibitory effect of GDF9 on androgen production 
by thecal cells was associated with a reduction of LH receptor and P450ssc mRNA (Spicer et 
al., 2008); whereas, the ability of GDF9 to stimulate thecal cell proliferation was more evident 
in small than in large follicles (Spicer et al., 2008). Apparently, the role of GDF9 was to 
prevent premature differentiation of both thecal and granulosal cells (Spicer et al., 2006; 2008).  
In addition to the previously described factors, estradiol and inhibin are important 
modulators of follicular function. Estradiol decreased progesterone production induced by LH, 
LH and insulin or LH and IGF-I in thecal cells. In contrast, estradiol had a potent stimulatory 
effect on production of androstenedione by thecal cells in either absence or presence of LH, LH 





appeared to form part of a paracrine positive feedback mechanism that stimulated further 
production of follicular estradiol by increasing androgen production by thecal cells (Spicer et 
al., 2005). On the other hand, inhibin, which is produced primarily by granulosal cells, plays 
important autocrine and paracrine roles in follicular physiology. Apparently, inhibin limits 
follicular estradiol production, because treatment of granulosal cells with an inhibin antibody 
increased estradiol production by 2 to 15 fold, compared with controls (Jimenez-Krassel et al., 
2003). Moreover, treatment of granulosal cells isolated from estrogen-active and estrogen-
inactive dominant follicles and subordinate follicles with anti-inhibin significantly increased 
estradiol production, indicating that inhibin was suppressing estradiol production by estrogen-
inactive and subordinate follicles (Jimenez-Krassel et al., 2003).  
In addition to the stimulatory role of FSH and LH in follicular development, two circulating 
substances, insulin and IGF-I, play important roles in modulating follicular growth (Spicer et 
al., 2002). Insulin and IGF-I increased FSH-stimulated estradiol production by granulosal cells 
from either small or large follicles. Likewise, individual or combined treatment of insulin and 
IGF-I stimulated basal and FSH-induced proliferation of granulosal cells from small and large 
follicles in a dose dependent manner (Spicer et al., 2002). Both IGF-I and IGF-II were locally 
identified in granulosa and theca, respectively, from follicles of different morphologic and 
functional characteristics (Yuan et al., 1998). Although IGF-II mRNA was detected in bovine 
thecal cells from diverse follicular developmental stages, no evidence for IGF-I mRNA 
expression was observed at any stage of development (Armstrong et al., 2000). It seems that 
IGF-II plays an autocrine role because IGF-II stimulated androstenedione and progesterone 





2004). Hence, both IGF-II and IGF-I play significant roles in steroidogenesis during follicular 
development. 
Follicular selection and dominance 
Ruminants have been used intensively in studies of ovarian follicular development. 
Particularly in cattle, morphological changes of the follicles during the estrous cycle have been 
associated with circulating hormones and functional characteristics of the follicles at different 
developmental stages. In addition to the feasibility to perform interesting in vivo studies, sheep 
represented a useful model to study aspects of follicular physiology in vitro.  
In ruminants, the later stages of antral follicle development occur in waves of follicular 
growth. During each reproductive cycle, follicular development was characterized by 
recruitment of several small follicles that grew progressively until the stage in which one or 
more were selected and continued their development; while the remaining follicles became 
smaller and progressively disappeared from the ovarian cortex (Ireland et al., 2000). In 
ruminants and other domestic species, emergence of each follicular wave is preceded or 
accompanied by a small increment of FSH concentration (Evans, 2003a) followed by 
upregulation of P450scc and P450arom in granulosal cells and gonadotropin receptors in 
steroidogenic cells (Bao and Garverick, 1998). Thus, the resultant greater steroidogenic 
capacity is an important physiological fact that influences the subsequent stages of follicular 
development.  
Follicular selection is the mechanism by which one or two follicles become morphologically 





et al., 1997b) and continue growing toward ovulation. The remaining follicles decreased in size 
and underwent atresia, most likely due to down regulation of LH receptor, StAR and 
steroidogenic enzymes (Xu et al., 1995a; Xu et al., 1995b; Bao et al., 1998), with the 
consequent reduction in estradiol synthesis that preceded apoptosis of granulosal cells (Austin 
et al., 2001; Clark et al., 2004). Follicular dominance was associated with greater expression of 
mRNA for LH receptor, P450scc, P450c17 and 3 HSD in thecal cells, and P450arom in 
granulosal cells, as compared with previous follicular stages (Xu et al., 1995b; Bao et al., 
1997a; Bao et al., 1997b). Dominant follicles (DF) had lower concentrations of IGF binding 
proteins (IGFBP) 2, 4, and 5 and greater concentrations of IGF-I than follicles prior to selection 
(Mihm et al., 1997; Austin et al., 2001). Likewise, onset of expression of LH receptor and 
3 HSD in granulosal cells was a remarkable indicator of the greater steroidogenic capacity of 
selected follicles (Bao et al., 1997a; Bao et al., 1997b; Beg et al., 2001), which apparently 
switch in gonadotropin dependence from FSH to LH (Mihm et al., 2006). Moreover, follicular 
size was highly correlated with concentrations of mRNA for P450arom (r = 0.77) and LH 
receptors in theca (r = 0.71) and granulosa (r = 0.54; Bao et al., 1997a). Expression of StAR, 
that was observed only in thecal cells, progressively increased as the dominant follicle grew 
(Bao et al., 1998), indicating that increasing synthesis of estradiol may require an increment of 
cholesterol transport in thecal cells to produce greater amounts of androgen, the substrate 
utilized by granulosal cells to synthesize estradiol.  
After the transient increase of FSH that precedes the emergence of each follicular wave, 
circulating concentrations of FSH decreased progressively within the following 24 h (Mihm et 





amounts of estradiol and inhibin secreted by selected follicles (Kaneko et al., 1997; Ginther et 
al., 2000a; Bergfelt et al., 2000). It was suggested that the decrease in circulating 
concentrations of FSH after the transient rise is associated with selection or deviation of the DF 
and atresia of the remaining subordinate follicles (Adams et al., 1993; Mihm et al., 1997; Beg 
et al., 2001). Administration of physiological concentrations of FSH delayed selection of the 
DF and subordinate follicles (Mihm et al., 1997). Apparently, follicles with greater amounts of 
gonadotropin receptors and steroidogenic capacity (Xu et al., 1995a; Xu et al., 1995b; Bao et 
al., 1998a; Bao et al., 1998b; Bao et al., 1998; Beg et al., 2001) were more competent to grow 
in an endocrine milieu low in FSH (Mihm et al., 1997; Ginther et al., 1999; Ginther et al., 
2000b). In contrast, subordinate follicles depended on FSH support and the reduced FSH 
concentration was a critical event that conferred them with metabolic disadvantages to grow at 
the same rate as the DF (Adams et al., 1993). However, subordinated follicles continued 
growing if adequate FSH was provided (Adams et al., 1993) or became dominant if the DF was 
removed (Ko et al., 1991; Ginther et al., 2001), indicating that they maintained the metabolic 
capacity to grow and were able to reach ovulatory status under appropriate endocrine influence.  
Evidence indicates that the IGF system is involved in follicular selection and dominance. 
The IGF system consists of two ligands (IGF-I and IGF-II), two receptors (IGFR1 and IGFR2), 
several IGF binding proteins (IGFBP) and IGFBP proteases (Spicer and Echternkamp, 1995; 
Monget et al., 1996). As documented above, IGF ligands play relevant functions in ovarian 
follicular development by stimulating granulosal cell proliferation and steroidogenesis (Spicer 
et al., 2002). The role of the IGF system in follicular deviation and subsequent dominance has 





granulosa and theca, respectively, with a significantly greater abundance in DF than 
subordinate follicles in both early- and mid-dominance (Yuan et al., 1998). Also, amounts of 
IGFBP2 were lower in DF than subordinate follicles in both follicular stages (Yuan et al., 
1998) and treatment of granulosal cells with FSH decreased IGFBP2 mRNA expression 
(Armstrong et al., 1998). In agreement with the previous findings, concentrations of IGF-I in 
follicular fluid were greater in the largest than in the smaller follicles (Echternkamp et al., 
1994; Beg et al., 2001). The IGFBP2 concentrations were significantly greater in the largest 
compared with the smaller follicles (Beg et al., 2001), coincident with the finding that 
proteolytic activity on IGFBP was greater in follicular fluid of estrogen-active than estrogen-
inactive follicles (Echternkamp et al., 1994; Rivera et al., 2001). Samples of follicular fluid 
from the two or three largest follicles collected on d 3 of the estrous cycle indicated that 
estradiol was greater and IGFBP4 was lower in the presumptive DF compared with 
subordinated follicles (Mihm et al., 2000). Apparently, an increment in the proteolytic activity 
on IGFBP and the consequent reduction of IGFBP concentrations in follicular fluid is a 
functional feature that distinguishes DF from subordinate follicles. Thus, the increased 
bioavailability of IGF-I under an appropriate gonadotropin stimulus mediates the greater 
capacity of DF to produce estradiol.  
In the ewe, as in the cow, emergence of each follicular wave is preceded by a transient 
increase of FSH (Souza et al., 1997; Evans, 2003b). During the estrous cycle, 2 to 4 groups of 
follicles grow in a wave-like pattern (Souza et al., 1998; Bartlewski 1999; Evans et al., 2000; 
Duggavathi et al., 2003). In the ewe, follicular dominance appears to be less evident than in the 





documented in sheep (Lopez-Sebastian et al., 1997; Gonzalez-Bulnes et al., 2001; 2004), recent 
authors have questioned the concept of follicular dominance as it occurs in cattle. The presence 
of a large estrogen-active growing follicle in the ovary did not prevent the emergence of a new 
follicular wave induced by exogenous FSH during the inter-wave FSH nadir (Duggavathi et al., 
2004). In addition, induction of physiological peaks of circulating FSH by exogenous 
administration of FSH every 2 to 2.5 d, stimulated the emergence of an extra follicular wave, 
but modified neither the occurrence of endogenous FSH peaks nor the subsequent follicular 
wave emergence (Duggavathi et al., 2004). Moreover, emergence and development of the 
induced follicular wave was not inhibited by the presence of the largest growing follicles 
belonging to the preceding endogenous FSH-induced follicular wave (Duggavathi et al., 2005). 
Using a different experimental approach, the peak and the amplitude of endogenous FSH was 
altered by elevated concentrations of estradiol released from implants placed on d 4 of estrous 
cycle (Barrett et al., 2006); as a consequence, emergence of a new follicular wave was 
prevented. However, despite supra-physiological concentrations of estradiol, administration of 
a physiological dose of FSH restored the emergence of follicles (Barrett et al., 2006). To 
support further the previous data, 2 or more large follicles from ultimate and penultimate waves 
of the estrous cycle may reach ovulatory status and eventually ovulate simultaneously (Souza et 
al., 1997; Bartlewski 1999). 
 After luteolysis is initiated by uterine PGF2 , concentrations of progesterone drop rapidly 
and the negative feedback exerted by this steroid in the hypothalamus and pituitary decline. 
The subsequent increased frequency of LH pulses during proestrus stimulates greater secretion 





secretion (Goodman and Inskeep, 2006). Thus, elevated concentrations of estradiol trigger an 
LH/FSH surge (Karsch et al., 1983). Greater mRNA concentrations for P450scc and 3 HSD in 
both granulosa and theca and P450-17 -hydroxylase in thecal cells were responsible for the 
elevated steroidogenic capacity of preovulatory follicles, mostly by providing substrate for the 
aromatization of androgen to estradiol in granulosal cells (Tian et al., 1995). Nevertheless, after 
an LH surge, the pattern of steroid secretion from the preovulatory follicle changed abruptly 
(Murdoch and Dunn, 1982; Fortune and Hansel, 1985). In the ewe and cow, a remarkable 
reduction of estradiol and androgen production followed the LH surge. Likewise, an abrupt 
increment in progesterone concentrations and the switch in pregnenolone/progesterone ratio 
from 1.6 h prior to LH to 0.18 h after the LH surge was indicated (Murdoch and Dunn, 1982; 
Fortune and Hansel, 1985). In addition, the transition in steroid production by preovulatory 
follicles from estrogen to progesterone dominance was associated with downregulation of 
P450-17 -hydroxylase and P450arom in thecal and granulosal cells, respectively, and 
upregulation of progesterone receptor (PR) in the two types of steroidogenic cells (Voss and 
Fortune, 1993a; Komar et al., 2001; Jo et al., 2002). Thus, the switch in steroid production by 
steroidogenic cells after the LH surge is part of the mechanism of differentiation of granulosal 
and thecal cells into large and small luteal cells of the insipient corpus luteum. Moreover, the 
amount of PR mRNA increased markedly and transiently in follicular cells of bovine 
periovulatory follicles within a few hours after the LH surge, followed by a second increase 
near the time of ovulation (Jo et al., 2002). Therefore, the first rise in PR mRNA may be 
associated with the sudden and simultaneous increases in follicular production of oxytocin, 





whereas the second rise in progesterone and PR mRNA may play an important role in the 
subsequent formation of the CL (Murdoch et al., 1986; Voss and Fortune, 1993a; Voss and 
Fortune, 1993b). 
The events that characterize follicular growth from the pool of primordial follicles 
throughout different developmental stages are summarized in Figure 1. Under appropriate 
stimuli by local and systemic hormones and growth factors, one or more large follicles become 
morphologically and functionally dominant while others undergo atresia. Ovulation occurs at 
the end of the follicular phase, once progesterone declines and increasing amounts of estradiol 






































































Result of communication between
follicles and adjacent stromal and
interstitial and endothelial cells
Constitutive expression of FSH
receptor.
FSH accelerates the rate at which
these follicles grow, but FSH is not
essential.
FSH stimulates E2 production by GC.
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LH receptors and P450c17 in TC.
Granulosal cells express LH receptors
and TC increase expression of LH
receptors .
Expression of LH receptors in GC
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LH support appears to be required
to maintain ovulatory competence. Atretic follicles
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bFGF, insulin, BMP-4 and BMP-7, Leukemia inhibitory factor (LIF)
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Intraovarian factors: GDF-9, BMP-15, bFGF, EGF, activin,
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inhibin
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Intraovarian factors: BMP system, estradiol, inhibin A,
activin A, follistatin, TGF , EGF, IGFI
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Expression of LHR in GC (Webb and
Campbell, 2007) and/or IGF system
(Fortune et al., 2004) is determinant
for selection of dominant follicle
Lack of appropriate LH support switches steroid
production from estrogen and testosterone to
progesterone. The follicle become estrogenically
inactive and apoptosis is initiated in all cellular
compartments of the follicle. Decrease of
intrafollicular estradiol has been shown to precede
apoptosis of GC that activates the controlled
degradation of ECM proteins by of MMPs and of
TIMPs. A reduction of estradiol also increases IGFBP.
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Figure 1. Summary of the events that characterize follicular development throughout different 






Physiologic aspects of luteal function 
After ovulation, the collapsed ovulatory follicle undergoes dramatic cellular and structural 
changes that confer to the new ovarian structure, the corpus luteum (CL), endocrine 
characteristics aimed to create physiological conditions that favor early embryonic 
development, implantation, placentation, and in general, assure success of gestation and 
survival of the specie. Thus, the CL constitutes the primary source of circulating progesterone. 
However, if fertilization of the oocyte does not occur, CL function decreases and a new 
reproductive cycle is initiatea a few days later. This physiological process is known as “corpus 
luteum regression” or “luteolysis”. Therefore, CL function is essential in all mammals for 
implantation and early maintenance of pregnancy and in the event of an infertile cycle its 
disappearance assures further opportunity for onset of a new gestation (Hoyer, 1998).  
Morphological characteristics of the corpus luteum 
The corpus luteum is a transient, highly vascularized, ovarian tissue that develops in a few 
days from a “corpus hemorrhagicus” to a mature CL, producing progressively greater amounts 
of progesterone (P4). From morphological and functional points of view, the CL has two 
different populations of cells: endocrine and non-endocrine cells that vary in proportion and 
number throughout the luteal phase (Rodgers and O'Shea, 1982; O’Shea et al., 1984; Rogers et 
al., 1984; Farin et al., 1986). Steroidogenic cells (SC) represent 55% of the cellular volume of 
the CL and consist of large (LLC) and small (SLC) luteal cells originated from granulosal and 
thecal cells of the ovulatory follicle (Hansel and Dowd, 1986), respectively. Nonsteroidogenic 





Rogers et al., 1984) and represent around 16% of the volume of the CL, considering that 
cellular matrix occupies 27% (Farin et al., 1986). Non-steroidogenic cells provide the structural 
architecture of the CL and synthesize several products that interact with steroidogenic cells and 
regulate steroid production (Girsh et al., 1996b; Juengel et al., 1998a; Korzekwa et al., 2008).  
Irregular shaped SLC, with a diameter < 20 m, produce low basal concentrations of 
progesterone (P4) under the influence of LH (Rodgers and O'Shea, 1982; Hoyer et al., 1984; 
Mamluk et al., 1998; Wiltbank, 1994), whereas round or polyhedral shaped LLC, whose 
diameter varies between 20 and 40 m in different mammalian species, secrete considerably 
greater amounts of P4 without pituitary luteotropic stimulus (Rodgers and O'Shea, 1982; Fitz et 
al., 1982; Bourdage et al., 1984; Wiltbank, 1994). Although number of LLC did not appear to 
change through different stages of luteal phase, including early periods of regressed CL, SLC 
significantly increased from Day 4 to 8 of the estrous cycle and maintained stable numbers 
until time of luteal regression when they began to decline (Farin et al., 1986). Apparently, 
hypertrophy of LLC and hyperplasia of SLC, fibroblasts and endothelial cells account for the 
dramatic increase in size and weight of the CL, often compared with tumor tissues (Juengel et 
al., 1998a). During CL development, a vast network of capillaries is established assuring 
sufficient blood flow to sustain the high metabolic rate of a completely mature CL (Bruce and 
Moor, 1976).  
Functional characteristics of the corpus luteum 
In most mammalian species, a luteotropic stimulus is partially or totally required to maintain 





stages of gestation. However, the influence of a specific pulsatile pattern of LH secretion 
appears to differ among species. In primates, for instance, luteolysis (Dubourdieu et al., 1991; 
Webley et al., 1991) or inhibition of luteal angiogenesis and progesterone production (Dickson 
and Fraser, 2000) were consequences of interruption of pulsatile LH secretion by using GnRH 
antagonists. In ruminants, lack of an appropriate pattern of LH secretion disrupted function of 
developing CL in heifers (Peters et al., 1994) but did not affect substantially any stage of luteal 
development in sheep (McNeilly et al., 1992). In other mammalian species, like the rabbit, 
estrogen is the main luteotropic hormone, while in the rat prolactin is primary and LH and 
estrogen play secondary roles (Holt, 1989; Freeman, 2006; Stouffer, 2006).  
Lifespan of the cyclic CL varies in different mammalian species. In primates and farm 
animals, cyclic CL persist between 12 and 16 days, whereas in rodents luteal phase is shorter (4 
or 5 day cycle) and is extended for about 1 to 2 or 3 weeks only in the event of 
pseudopregnancy or a fertile cycle, respectively (Leymarie and Martal, 1993; Freeman, 2006). 
In other animals like carnivores (dogs, wolves, foxes, cats, etc), the length of the luteal phase in 
pregnant or nonpregnant females does not differ appreciably (Stouffer, 2006). On the other 
hand, while in many mammals the CL is not absolutely indispensable throughout gestation 
(sheep, horse, rat, human, monkey) because luteal P4 is replaced by placental secretion of P4, 
some animals such as cow, pig, goat and rabbit require luteal function during the entire 
gestation period (Tanabe, 1966; McDonald et al., 1952; Allen, 2001). 
At the end of the ovarian cycle, the absence of viable embryos in the uterus allows luteolysis 
to take place. In many species, including domestic farm animals (such as the ewe, cow, goat, 





endogenous luteolytic substance, prostaglandin F2  (PGF2 ), released from the uterine 
endometrium, restrains P4 production and induces CL regression (Wiltbank and Casida, 1956; 
Malven and Hansel, 1964; McCracken et al., 1970; Hilliard, 1973; Currie and Thorburn, 1974; 
Gleeson et al., 1974; Douglas and Ginther, 1976; Douglas et al., 1976). In most of these 
species, transfer of PGF2  from utero-ovarian vein toward ovarian artery appears to be an 
important component of the mechanism by which this hormone reaches the luteal tissue 
(Ginther, 1974); given that close anatomical relationship between uterine vein and ovarian 
artery (Del Campo and Ginther, 1972; 1973a; 1973b; Ginther and Del Campo, 1974), and 
functional connection among uterus and CL (Wiltbank and Casida, 1956; Malven and Hansel, 
1964; Inskeep and Butcher, 1966; Barley et al., 1966; Currie and Thorburn, 1974; Gleeson et 
al., 1974; Gleeson, 1974; Pexton et al., 1975a) were demonstrated. In contrast, in the mare, 
uterine and ovarian vasculature seems to be anatomically more independent (Ginther et al., 
1972; Del Campo and Ginther, 1973a) and plays a less significant role in luteolysis (Douglas 
and Ginther, 1975). Although in primates an extensive area of contact between utero-ovarian 
vein and ovarian artery exists (Ginther et al 1974), raising the possibility that a local diffusion 
mechanism takes place, no functional association among uterus and CL has been indicated 
(Neill et al., 1969; Castracane et al., 1979), and even, the role of PGF2  as a luteolytic agent in 
these species has been controversial and several substances have proposed as luteotropic factors 
(Zeleznik and Clifford, 2006). However, a cumulative bulk of evidence indicates that luteal 
PGF2  mediates luteolysis in primates (Auletta et al, 1984; Johnson et al., 1988; Houmards et 
al., 1989; Zelinski-Wooten, et al., 1990; Bennegard et al., 1991; Bogan et al., 2008; Priyancka 





Factors affecting lifespan of the corpus luteum 
The events conducive to secretion of PGF2  from the uterus have been described in detail in 
ruminants. Luteolysis during the estrous cycle was believed to occur as consequence of a 
reciprocal positive feedback mechanism between luteal oxytocin and uterine PGF2  
(McCracken et al., 1984; Lafrance and Goff, 1988; Lamsa et al., 1989). This mechanism was 
proposed to be responsible for the episodic secretion of PGF2  necessary to complete luteal 
regression (Flint et al., 1990); furthermore, this process occurs at a specific time of the estrous 
cycle (Lafrance and Goff, 1988; Silvia et al., 1991; Kieborz-Loos et al., 2003). Progesterone 
suppressed secretion of PGF2  when more P4 receptors were present, presumably by inhibition 
of synthesis of oxytocin receptors early in the estrous cycle when the uterus was more 
responsive to P4 (McCracken et al., 1984; Hazzard et al., 1998; Kieborz-Loss et al., 2003). 
However, as the estrous cycle progressed, concentrations of P4 receptors decreased, which in 
turn allowed the synthesis of estrogen and oxytocin receptors (McCracken et al., 1984). As a 
result, the uterus became more responsive to luteal oxytocin and a positive feedback 
mechanism was apparently established between oxytocin and endometrial PGF2 .  
A period of progestational influence appears to be important in the timing of luteal 
regression. Treatment with exogenous P4 on day 0 or 1 after estrus advanced the occurrence of 
the first peak of PGF2  and shortened the length of the estrous cycle in sheep (days 8 and 11 for 
P4-treated ewes and days 12.3 and 17 for control ewes, respectively; Ottobre et al., 1980). In 
addition, the blockade of P4 receptors by mifepristone (RU 486) during the early to mid-luteal 





due to delayed PGF2  secretion from the endometrium (Morgan et al., 1993). Abolition of P4 
source on days 12 or 14 by removal of either ovaries or CL in sheep, resulted in a temporal 
increase of PGF2  followed by a gradual decline (Ottobre et al., 1984; Vincent et al., 1986); it 
was suggested that continued secretion of P4 is necessary for secretion of PGF2  to continue 
beyond day 14 of the estrous cycle. Apparently, P4 regulates secretion of PGF2  early in the 
estrous cycle by timing the initial peaks of secretion, and thereafter, by modulating secretion of 
PGF2  until luteal regression is completed. However, in postpartum cows and anestrous ewes 
the absence of a previous exposure of the uterus to P4 followed by estrogen prior to first 
ovulation alters the physiological conditions of the uterus and as a consequence, the timing of 
luteolysis is premature (Inskeep, 2004). 
At the time when PGF2  was identified as the luteolytic agent (McCracken et al., 1970), and 
the anatomical and functional relationship between uterus and CL were pointed out (Ginther, 
1974), suppression of PGF2  secretion was the most likely mechanism to prevent luteolysis in 
pregnant animals. However, secretion patterns of PGF2  in pregnant and nonpregnant sheep in 
the late luteal phase were similar (Pexton et al., 1975b), indicating that in pregnant females 
luteolysis is prevented by mechanisms other than suppression of PGF2  secretion, for example 
amounts of PGF2  transported or metabolized, or amount of PGF2  assimilated by luteal tissue 
(Pexton et al., 1975c; Lewis et al., 1977). Beside the luteoprotective effect of the embryos in 
the uterus (Inskeep et al., 1975; Pratt et al., 1977; Thatcher et al., 1986), uterine PGE2 appears 
to be important to prevent luteolysis in pregnant sheep (Lewis et al., 1978; Pratt et al., 1979; 





Physiological and molecular aspects of luteal regression 
Luteal regression involves two consecutive and complementary mechanisms whereby the 
CL loses steroidogenic capacity (functional luteolysis) without apparent changes in cellular 
structure and undergoes subsequent degradation of all cellular and structural components 
(structural luteolysis). The latter mechanism implies a concomitant reduction of luteal weight 
and size; and finally, the CL becomes a fibrotic nonfunctional tissue named “corpus albicans”. 
These mechanisms are triggered at the end of the luteal phase after uterine PGF2  activates its 
receptors in different luteal cell types. Hence, luteolysis is a complex and orchestrated 
physiologic processes involving not only steroid secreting cells but also endothelial and 
immune cells that through autocrine and paracrine mechanisms drive a sequence of cellular and 
vascular events conducive to demise of the CL (reviewed by Hoyer, 1998; McCracken et al., 
1999; Niswender et al.,  2000; Stocco et al., 2007).  
PGF2  reduces essential enzymes for progesterone synthesis during functional luteolysis 
An abrupt increase in the amplitude, duration and number of pulses of PGF2  at the end of 
the luteal phase (Pexton et al., 1976; Nett et al., 1976a; Zarco et al., 1988a) marks the onset of 
luteal regression. A few hours later, concentrations of peripheral P4 are minimum and size and 
weight of the CL are smaller (Zarco et al., 1988b; Tsai et al., 2001). Furthermore, reduction in 
P4 secretion after exogenous PGF2  administration was accompanied by a simultaneous 
decrease in blood flow (McCracken et al., 1970; Nett et al., 1976b; Niswender et al., 1975), 
which implies less nutrient and luteotropic stimuli to sustain steroid production by large and 





After PGF2  binds to its luteal receptor, it triggers changes in expression of genes and 
activity of proteins associated with P4 synthesis. Apparently, P450ssc mRNA and protein 
activity are not down regulated by PGF2  before plasma P4 declines below functional 
concentrations (Tian et al., 1994; Rogers et al., 1995; Diaz and Wiltbank, 2005). Although 3 -
HDS mRNA decreased concurrently with P4 concentration (r = 0.76, p < 0.005) during the first 
12 h after a luteolytic dose of PGF2  (Tian et al., 1994; Tsai et al., 2001), neither the amount of 
protein nor enzyme activity decreased within 24 h following PGF2  (Rogers et al., 1995; 
Juengel et al., 1998b). Tubulin, a component of the cytoskeleton associated with transport of 
cholesterol to the outer mitochondrial membrane, decreased markedly before decline of P4 in 
PGF2 -induced luteolysis in sheep (Murdoch, 1996). Moreover, mRNA encoding steroidogenic 
acute regulatory protein (StAR), a protein involved in transport of cholesterol from the outer to 
the inner mitochondrial membrane, was down regulated a few hours after exogenous PGF2  in 
sheep, sows and cows (Juengel et al., 2000; Tsai et al., 2001; Diaz and Wiltbank, 2005). In 
addition, transcript concentration for LH receptor in luteal tissue decreased significantly in a 
lapse of 4 to 9 h after PGF2 -induced luteolysis in cows and sheep (Juengel et al., 2000; Tsai et 
al., 2001) but not in sows (Diaz and Wiltbank, 2005). Thus, abolition of luteotropic stimulus 
and transport of cholesterol through cytoplasm and the mitochondrial membrane appears to be 
the target of PGF2  to reduce steroidogenic capacity of CL during functional luteolysis. 
However, reduction of P4 production and oligonucleosome formation after a subluteolytic dose 
of PGF2  was reversed a few hours later (Juengel et al., 2000). Apparently a continuous pattern 
of episodic PGF2  secretion is necessary to induce irreversible changes in the functional and 





Role of blood flow in luteolysis 
The effect of endogenous and exogenous PGF2  on reduction of luteal blood flow 
concurrently with diminution of P4 concentrations during the estrous cycle has been described 
as a normal physiological event in the ewe (McCracken et al., 1970; Niswender et al., 1975; 
Niswender et al., 1976; Nett et al., 1976). Whether PGF2  has a direct effect on ovarian blood 
flow or blood flow declines as a consequence of the reduction of P4 production by luteal cells 
(or vice versa) has been uncertain. However, in recent years evidence has accumulated 
indicating a role of PGF2  in the hemodynamic changes associated with luteolysis. The 
presence of PGF2  receptors (FP) in endothelial cells was reported in the cow and sow 
(Mamluk et al., 1998; Zanoni et al., 2007). Also, acute increases in blood flow followed by a 
progressive reduction at the end of the luteal phase and after administration of PGF2  in mid-
phase bovine CL were associated as a component of the luteolytic cascade (Acosta et al., 2002; 
Shirasuna et al., 2008). Moreover, this acute increase in luteal blood flow during spontaneous 
luteolysis was accompanied by an increase in plasma PGFM (15-keto, 13,14dihydro-PGF2 , 
inactive metabolite of PGF2 ) (Shirasuna et al., 2008).  
Endothelin 1 (END1), a vasoactive peptide produced by luteal endothelial cells, increased at 
the end of the luteal phase or after an exogenous dose of PGF2  (Girsh et al., 1996b; Ohtani et 
al., 1998; Wright et al., 2001; Choundhary et al., 2004; Shirasuna et al., 2008). END1, whose 
potent vasoconstrictor effect has been demonstrated in many tissues, activates receptors in 
luteal endothelial cells (Mamluk et al., 1999; Klipper et al., 2004) and may be responsible for 





physiological effects, END1 decreased P4 concentrations in vitro and in vivo and is involved in 
PGF2 -induced luteolysis in sheep and cows (Hinckley and Milvae, 2001; Doerr et al., 2008; 
Keator et al., 2008), as will be described in detail later in this review.  
Nitric oxide (NO), another vasoactive substance synthesized by luteal endothelial cells) was 
reported to modulate luteal production of P4 in vivo and in vitro (Jaroszewski and Hansel, 
2000; Jaroszewski et al., 2002; Jaroszewski et al., 2003; Skarzynski et al., 2003; Korzekwa et 
al., 2004) and may play a role acting as a component of autocrine and paracrine actions during 
luteolysis (Jaroszewski et al., 2003). Nitric oxide, a gas synthesized by deamination of the 
amino acid L-arginine through catalytic action of NO synthase (NOS), is secreted from 
endothelial cells causing relaxation of vascular smooth muscular cells by binding and activating 
guanylyl cyclase to produce cyclic GMP (Alberts et al., 2002); and is an important modulator 
of local blood flow in the tissues (Moncada and Higgs, 2006). Luteal endothelial NOS (eNOS) 
mRNA and protein increased at the end of the luteal phase (coincident with the time of onset of 
luteolysis) or after exogenous PGF2  in cows and sheep, respectively (Skarzynski et al., 2003; 
Vonnahme et al., 2006; Shirasuna et al., 2008), whereas only eNOS protein increased after 
PGF2  in the rabbit (Boiti et al., 2003).  
Recently, it was reported that administration of NO donor into the CL induced an acute 
increase in luteal blow flow within 30 min after injection and reduced the length of the estrous 
cycle in cows (Shirasuna et al., 2008). In contrast, intraluteal injections of a NO inhibitor 
suppressed the increase of luteal blood flow and delayed the onset of luteolysis in response to 
exogenous PGF2  (Skarzynski et al., 2003; Shirasuna et al., 2008). In addition, partial pressure 





significantly in cows after a luteolytic dose of PGF2  during the mid-luteal phase (Skarzynski et 
al., 2003; Acosta et al., 2008); and both events were temporally associated with the increase of 
luteal blood flow and preceded the decline of P4 concentrations (Acosta et al., 2008). Moreover, 
infusion of a NO inhibitor increased concentration of P4, decreased plasma concentration of 
nitrite/nitrate and extended the lifespan of the CL (Skarzynski et al., 2003). Accordingly, the 
increase in luteal blood flow caused by NO and the consequent enhancement of vascular 
permeability may promote infiltration of immune cells and other substances into the CL, 
contributing to the successive events involved in the mechanism of structural luteolysis (Acosta 
et al., 2008). Whether the increase in blood supply to the CL within few minutes after PGF2  
triggers the luteolytic cascade as was suggested (Acosta and Miyamoto, 2004) or is only a 
component of the intricate mechanism of luteolysis have to be further confirmed. 
Active participation of immune system in luteolysis 
According to Pate and Keyes (2001), the role of immune cells in luteal regression may be 
explained by their participation in the loss of steroidogenic capacity and destruction of the 
luteal tissue, and by modulation of the potential inflammatory conditions originated by 
degenerating luteal cells with the aim of preserving basic environmental conditions for those 
cells that have not died. Population of immune cells in CL is represented by T-lymphocytes, 
macrophages-monocytes and eosinophils (Bagavandoss et al., 1988; Pate, 1994; Bukovsky et 
al., 1995; Best et al., 1996; Penny et al., 1999; Bauer et al., 2001 Townson et al., 2002), whose 
number increased as the mid-luteal phase progressed (Bauer et al., 2001; Townson et al., 2002); 





PGF2 -induced luteolysis (Penny et al., 1999; Bauer et al., 2001; Townson et al., 2002). 
Leucocytes increased around 20% at the end of the luteal phase and 70% at late luteal 
regression; this increment was due to infiltration of monocytes and local proliferation of 
macrophages when capillaries were no longer present (Bauer et al., 2001). During structural 
luteolysis macrophages play an important role by phagocytizing dead cells and cell debris 
(Paavola and Boyd, 1979) as well as releasing cytokines, oxygen radicals and substances that 
inhibit steroidogenesis (Hoyer, 1998; Pate and Keyes, 2001), 
Infiltration of macrophages appears to be regulated by chemokines (Pate and Keyes, 2001), 
particularly monocyte chemoattractant protein 1 (MCP-1), a cytokine detected in greater 
quantity during luteal regression in coincidence with the influx of macrophages (Bowen et al., 
1996; Penny et al., 1998) or 4 to 8 h after PGF2 -induced luteolysis (Haworth et al., 1998; Tsai 
et al., 1997; Penny et al., 1999). Analysis of MCP-1 mRNA expression in bovine CL revealed a 
significant increment as early as 0.5 h after PGF2 -induced luteolysis and continued for at least 
64 h (Kliem et al., 2009); whereas the expression of its receptor was greater from 12 until 64 h 
after PGF2 . MCP-1 was detected in endothelial cells (Cavicchio et al., 2002). Once expressed 
in vascular tissue, MCP-1 stimulated migration of immune cells, particularly monocytes, 
macrophages and T-lymphocytes, from blood vessels into tissues undergoing inflammation 
(Mukaida et al., 1998). Townson et al. (2002) documented that MPC-1 mRNA and protein 
expression as well as immune cell accumulation in bovine CL preceded the onset of 
spontaneous luteolysis by several days. If luteolysis was prevented between days 16 to 18 of 
the cow estrous cycle, no increase in MCP-1 or macrophage infiltration was observed (Penny, 





secretion by endothelial cells (Cavicchio et al., 2002), indicating that this chemoattractant may 
be released as an indirect action of PGF2 . According to the proposed model by Penny (2000), 
at the end of the luteal phase PGF2  stimulated, directly or indirectly, secretion of MCP-1 and 
other cytokines by several luteal cell types (lymphocytes, macrophages, fibroblasts, and 
steroidogenic and endothelial cells) causing an influx of macrophages that play an essential role 
during structural regression of the CL .  
Once immune cells become activated within an inflamed tissue, they secrete cytokines, such 
as tumor necrosis  (TNF- ), interferon  (IFN- ) and interleukin 1  (IL-1 ). In addition to 
modulating the immune response during luteal regression, these cytokines directly affect luteal 
steroidogenic cells, suppressing progesterone production and inducing apoptosis (Friedman et 
al., 2000; Pate and Keyes, 2001; Petroff et al., 2001). A significant increase of mRNA 
expression of TNF- , IFN- , and IL-1  was detected as early as 2 h after PGF2 -induced 
luteolysis (Neuvians et al., 2004a). Moreover, this increment was simultaneous with a decline 
of LHR and P450scc mRNA (Neuvians et al., 2004a); which supports the suppressive effect of 
these immune mediators on P4 production by luteal tissue (Fairchild and Pate, 1991; Benyo and 
Pate, 1992; Young et al., 1997). In another study, increases of TNF-  and IFN-  mRNA 0.5 
and 2 h after PGF2 , respectively, were reported (Kliem et al., 2009), followed by increases in 
TNF-  receptor mRNA and protein at 2 and 12 h, respectively. TNF-  receptor was identified 
in endothelial cells from microvascular tissue of bovine CL (Okuda et al., 1999) as well as in 
SLC and LLC (Friedman et al., 2000). In addition, expression of TNF-  receptor mRNA 





Evidence indicates that both TNF-  and IFN-   are highly cytotoxic (Benyo and Pate, 1992; 
Friedman et al., 2000; Petroff et al., 2001). Cultured luteal cells treated with TNF-  and IFN-  
had less cell viability than untreated control cells and these cytokines induced DNA 
fragmentation by 48 h after cytokine treatment (Petroff et al., 2001). Immune cytokines 
stimulated greater secretion of luteal PGF2  in vitro than control untreated cells (Fairchild and 
Pate, 1991; Benyo and Pate, 1992; Petroff et al., 2001). However, IFN- -induced elevation of 
luteal PGF2  was reversed by P4 (Fairchild and Pate, 1991), indicating a protective effect of P4 
on luteal function that was also demonstrated by reducing TNF- -induced cytotoxicity in 
endothelial cells treated with P4 (Friedman et al., 2000). In this regard, Juengel et al. (2000) 
observed that a subluteolytic dose of PGF2  (3 mg/6 kg BW) in the ewe transiently suppressed 
serum concentrations of P4 and caused formation of oligonucleosomes 9 h after treatment and 
thereafter disappeared without any effect on CL weight.   
In conclusion, after luteolysis is initiated by uterine PGF2 , secretion of MCP-1 by luteal 
cells (Penny, 2000) induces infiltration of macrophages and T-lymphocytes into the CL (Penny 
et al., 1999; Townson et al., 2002). These leukocytes secrete immune cytokines such as TNF- , 
IFN-  and IL-1  that stimulate luteal PGF2  secretion and suppress P4 production by 
steroidogenic cells, reinforcing the cascade of luteolytic events (Pate and Keyes, 2001). In 
addition, immune cytokines have a direct effect on viability of endothelial and steroidogenic 







Apoptosis during structural luteolysis 
After uterine PGF2  disrupts synthesis and secretion of P4 from steroidogenic cells, luteal 
PGF2  directly and/or through several luteolytic mediators (like NO, END1, TNF- , IFN- , IL-
1 ) triggers structural luteolysis that involves cellular apoptosis, phagocytosis of endothelial 
and steroidogenic cells, and degradation of cellular matrix (Hoyer, 1998; Pate and Keyes, 2001; 
Smith et al., 2002; Stocco et al., 2007).  
Apoptosis or programmed cell death is a highly regulated physiological mechanism for 
reducing non-necessary populations of cells for the normal function of the tissue, or during 
specific developmental stages. Albert et al. (2002) described structural changes of the apoptotic 
cell as follow: “the cell shrinks and condenses, the cytoskeleton collapses, the nuclear 
membrane disassembles and the nuclear DNA breaks up into fragments”. As a final cellular 





endonucleases that cleave DNA into 185-bp DNA fragments (Tilly, 1996). So, degradation of 
DNA and the consequent formation of oligonucleosomes is considered a hallmark of apoptosis 
(Compton, 1992) and has been identified during luteal regression in human beings (Shikone et 
al., 1995; Sugino et al., 2000a), sheep (Sawyer et al., 1990; Rueda et al., 1995a), cows 
(Friedman et al., 2000; Petroff et al., 2001), sows (Bacci et al., 1996) and rats (Matsuyama et 
al., 1996). 
During functional luteolysis, the anti-apoptotic effect of P4 is suppressed and luteal PGF2 , 
directly or via autocrine and paracrine mediators, initiates progressive destruction of all cellular 





concentrations declined and structural regression started; evidence that also was observed by 
Murdoch (1995). Content of DNA in bovine CL decreased from about 9.5 mg/CL at the mid-
luteal phase to 2.2 mg/CL at the time of luteolysis (days 18 to 21 of the estrous cycle) (Zheng et 
al. 1994); whereas weight of CL and luteal content of P4 decreased 73% and 98% respectively, 
and the number of cells dying during luteolysis was approximately 77.8×10
6
 per day. 
Fragmentation of DNA was first observed 12 h after exogenous PGF2  in the ewe (Sawyer et 
al., 1990; Rueda et al., 1995) and by 6 h in the sow (Bacci et al., 1996). Endothelial cells 
appeared to be the first population of cells targeted by PGF2 -induced apoptosis (Sawyer et al., 
1990; Rueda et al., 1995; Bacci et al., 1996; Gaytan et al., 1998). In the sow, loss of capillaries 
increased progressively from 15% at 6 h after PGF2 -induced luteolysis to 49% 36 h later 
(Bacci et al., 1996). However, new morphological signs of apoptosis in parenchymal cells were 
not observed until 48 h after PGF2  (Bacci et al., 1996). In regressing ovine CL, endothelial 
cells with normal nuclei declined significantly at 12 h after PGF2 , followed by steroidogenic 
cells and fibroblasts at 24 and 36 h, respectively (Sawyer et al., 1990). Also, apoptotic cells in 
buffalo cows increased 18 h after PGF2  (Yadav et al., 2005). 
Apoptosis is mediated by a variety of proteins activated by stimuli originated inside 
(intrinsic pathway) or outside (extrinsic pathway) the cell. In the first case, several factors (such 
as hypoxia, hyperoxia, hormone deprivation, radiation, etc) can induce changes in the 
permeability of the mitochondrial membrane that trigger a cascade of intracellular events that 
involve several proteases named caspases. In the second case, an apoptotic cascade is 
originated by activation of a membrane receptor (Fas receptor; FasR) by Fas ligands (FasL) 





during cellular stress is regulated by changes in the Bcl-2 family of proteins that have anti-
apoptotic (Bcl-2 and others) and pro-apoptotic (Bax, Bad, etc) activity (Tilly, 1996). The ratio 
of Bax to Bcl-2 appears to be important to determine cell survival. Concentrations of Bax but 
not Bcl-2 mRNA and protein increased within 4 h after PGF2 -induced luteolysis in buffalo 
cows (Yadav et al., 2005); the Bax/Bcl-2 ratio was 4 fold greater compared with time 0 
(PGF2  injection). Both caspases 3 and 9 proteins and activity increased after PGF2 , but 
caspase 9 increased earlier (4-12 h) than caspase 3 (18 h) (Yadav et al., 2005). During induced 
luteolysis in cows, mRNA expression of p53 (another apoptotic protein) and Bax increased 
significantly from 24 to 64 h after PGF2 , whereas Bcl-XL showed a significant increase only 
from 48 to 64 h (Kliem et al., 2009). In addition, caspases 3, 6 and 7 were greater at 12, 2 and 2 
h after PGF2 , respectively, than at time 0.  
In human CL, the expression of Bcl-2 and Bax mRNA was examined during the menstrual 
cycle. Results revealed that Bcl-2 protein was lower in the regressing CL than in mid-luteal 
phase and early pregnancy (Sugino et al., 2000a), whereas Bax protein was greater in the 
regressing CL than during mid-luteal phase and early pregnancy. In addition, mRNA 
expression during luteolysis followed the same pattern with greater expression level for Bax 
and lower for BCL-2 (Sugino et al., 2000a). Interestingly, hCG incubated with luteal tissue 
significantly decreased mRNA and protein of Bax and significantly increased those of Bcl-2 
(Sugino et al., 2000a). In this regard, blockade of P4 receptor in cultured bovine luteal cells 
increased FasR and caspase 3 mRNA expression and caspase 3 activity (Okuda et al., 2004), 
supporting the concept that apoptosis is a hormone-regulated process in which luteotropic 





Intrinsic apoptosis during luteal regression has been associated with an increase of reactive 
oxygen species (ROS), and with the consequent oxidative stress (Hoyer, 1998). During 
luteolysis, production of ROS was increased in the CL by several mechanisms involving 
PGF2 , macrophages and hemodynamic changes (Sugino, 2006). As a consequence, 
accumulation of ROS causes DNA and protein damage and cell membrane alterations that 
trigger apoptosis (Sugino, 2006). In addition, the CL and other tissues have specific enzymes 
that counteract superoxide radical accumulation (Sugino et al., 2000b). Copper-zinc and 
manganese superoxide dismutase (SOD) mRNA and protein, and lipid peroxide concentrations 
during the human menstrual cycle and early pregnancy were evaluated (Sugino et al., 2000b). 
Copper-zinc SOD mRNA and activity reached the lowest amount during luteal regression and 
the greatest amount during pregnancy. In contrast, manganese SOD mRNA and activity were 
greater in regressing CL than at any other luteal stage (Sugino et al., 2000b), concurrently with 
higher amounts of lipid peroxide concentration.  
On other hand, FasL was significantly up-regulated 0.5 h after PGF2  and attained the 
highest increment at 12 h; while FasR increased from 2 h until 64 h after PGF2  (Kliem et al., 
2009). Both proteins, FasL and FasR, have been implicated in the regulation of cellular 
apoptosis during structural luteolysis (Taniguchi et al., 2002). FasR transcript was detected in 
bovine CL with a significantly greater expression during luteal regression than in any other 
stage (early, mid and late CL) (Taniguchi et al., 2002). Also, FasR mRNA expression increased 
1.4 and 1.8 fold in cultured luteal cells treated with INF  alone and INF  combined with TNF , 
respectively (Taniguchi et al., 2002). Moreover, treatment of luteal cells with FasL combined 





whereas FasL alone was not cytotoxic. Although FasR was expressed in luteal cells in the 
absence of cytokines, the presence of FasL in the culture did not induce apoptosis, supporting 
the role of the immune cytokines in the sequence of events leading to luteal regression.  
Cellular matrix degradation and structural luteolysis 
In the ovary, as in other tissues, the space between cells is occupied by a network of 
macromolecules, proteins and polysaccharides that constitute the structural support of the tissue 
and interact with the cells, influencing their survival, development, migration, proliferation, 
shape and function (Albert et al., 2002). This “substance around the cells” is named 
extracellular matrix (ECM). In the ovary, ECM is object of continuous remodeling to provide 
basic cellular conditions to each developmental stage and functional structure. Stability of 
ECM is a consequence of differential expression of two important groups of proteins: matrix 
metalloproteinases (MMP) that degrade certain components of ECM (Pitzel et al., 2000) and 
tissue inhibitors of metalloproteinases (TIMP) that inhibit MMP activity (Ricke et al., 2002a).  
MMP proteins are zinc- and calcium-dependent enzymes that degrade proteinaceous 
components of the ECM and cleave signaling proteins. This group consists of more than 26 
members synthesized as inactivated enzymes (pro-MMP) and classified in collagenases, 
gelatinases, stromelysins and membrane type MMP (Smith et al., 2002). TIMP include a group 
of 4 proteins (TIMP-1, -2, -3 and -4) that specifically inhibit MMP and can regulate cellular 
functions by mechanisms different to MMP inhibitor activity (Smith et al., 2002). TIMP are 





2008), inhibit angiogenesis (Seo et al., 2003) and apoptosis (Guedez et al., 1998) and promote 
steroidogenesis (Shores and Hunter, 2000) and other functions. 
During its lifespan, a CL undergoes an intensive remodeling of the ECM that is hormonally 
regulated by luteotropic, luteolytic and steroidogenic stimuli at the level of transcription, 
secretion and activation of proenzymes (Smith et al., 2002; Vassilev et al., 2002). 
Modifications of MMP and TIMP mRNA expression and protein activity were associated with 
structural regression of the CL in rats (Liu et al., 1999), pigs (Pitzet el al., 2000) and sheep 
(Ricke et al., 2002 a, b). Members of MMP and TIMP families have been identified and 
monitored in luteal tissue of several species during the estrous cycle and luteolysis (Liu et al., 
1999; Pitzel el al., 2000; Ricke et al., 2002 a, b, c; Towle et al., 2002; Ribeiro et al., 2006 , 
2007; Kliem et al., 2007). Expression of TIMP-2 mRNA was demonstrated in ovine 
preovulatory follicles and CL throughout the luteal phase (Smith et al., 1995). Concentrations 
of TIMP-2 in luteal tissue were maximal during the early luteal phase (d 3 and 7 post estrus) 
and minimal on d 16, when probably luteolysis was taking place. Also, TIMP-2 mRNA 
concentration was 10 times greater in LLC than in SLL, indicating that probably LLC are the 
primary source of TIMP-2 as reported elsewhere (Smith et al., 1994; Ricke et al., 2002b). 
Amounts of MMP-2 and MMP-14 mRNA followed a different expression pattern during the 
estrous cycle in sheep (Ricke et al., 2002c). At day 5, MMP-14 attained greater expression and 
decreased in mid- and late-luteal phase; whereas MMP-2 was greater on day 10 compared with 
earlier stages.  
In ovine tissue of mid-luteal phase, TIMP-1 and TIMP-2 decreased abruptly (60% and 90% 





h 8. In contrast, MMP-2 and MMP-9 activities increased 165% at 8 h after PGF2 , coinciding 
with the lowest concentration of P4 (Towle et al., 2002). In another report in sheep, TIMP-1 
concentration significantly decreased 15 min after administration of PGF2  (time 0) and 
remained at basal values through 48 h (Ricke et al., 2002a). In addition, TIMP-1 mRNA 
decreased 1 h after PGF2  and increased at 4 and 6 h, whereas TIMP-2 and TIMP-3 mRNA 
remained lower throughout the first 6-h period and then significantly increased (Ricke et al., 
2002a). The study of mRNA expression and activity of various members of the MMP family 
(MMP-1, -2, -3 , -7 , -13 and -14) in the ewe CL after PGF2 -induced luteolysis revealed an 
increase in mRNA of all MMP members (except MMP-2) 15 to 30 min post PGF2  (Ricke et 
al., 2002b). All MMP mRNAs were greater than at time 0 (previous to PGF2 ) by 6 h after 
PGF2 , and MMP activity increased significantly by 15 min and remained elevated through 48 
h post- PGF2  (Ricke et al., 2002b). Thus, modification in the expression pattern and activity of 
MMP and TIMP mRNA and protein may increase the MMP/TIMP ratio, facilitating ECM 
degradation and consequently favoring structural luteolysis (Smith et al., 2002). 
In mid-phase bovine CL, MMP-1 mRNA expression increased abruptly 2 h after PGF2 -
induced luteolysis, followed by MMP-9 (12 h), and MMP-2 and MMP-14 (24 h). TIMP-2 
mRNA initially remained at same amounts of h 0 luteal tissue (previous to PGF2 ) and 
decreased precipitously at h 48; whereas TIMP-1 increased at h 12 and declined 36 h later 
(Kliem et al., 2007). In addition, mRNA expression of plasminogen activator system (PAS) 
revealed an abrupt increase as early as 2 to 4 h after PGF2 . PAS is involved in ECM 





Roles of uterine and luteal PGF2  in luteal regression 
As mentioned above, absence of viable embryos in the uterus at the end of each luteal cycle 
allows increased secretion of PGF2  (Zarco et al., 1988) that through diffusion from venous to 
arterial blood vessels reaches the ovary and binds to specific PGF2  receptors (FP) localized in 
the surface of LLC (Fitz et al., 1984; Balapure et al., 1989; Gadsby et al., 1990). Activation of 
FP triggers a cascade of molecular events conducive to the demise of the CL and the onset of a 
new reproductive cycle.  
Biochemical characteristics, synthesis, and transport of PGF2  
Prostaglandins (PG) are members of a group of biomolecules containing 20-carbon 
backbone structure known as eicosanoids, that play essential functions in the reproductive 
physiology of mammals (Weems et al., 2006; Flores and Barlund, 2009). In addition to PG, the 
eicosanoid family includes thromboxanes and leukotrienes. Biologically active prostaglandins 
include 3 members: PGI2, PGE2 and PGF2 . Prostaglandins are synthesized from arachidonic 
acid (an important polyunsaturated fatty acid of the cellular membrane) and hence have a lipid 
nature (Marnett et al., 1999). Phospholipase A2 catalyzes release of arachidonic acid from 
cellular membrane, followed by oxygenation and peroxidation of arachidonic acid in the 
reticulum endoplasmic to yield PGG2 and PGH2 (Marnett et al., 1999). This step is comprised 
of two successive reactions catalyzed by a single bifunctional enzyme: prostaglandin 
endoperoxide synthase or prostaglandin G/H synthase (Cox). At least 2 forms of Cox have been 
identified; Cox-1 is expressed constitutively and Cox-2 is an inducible isoform (Smith et al., 





components of the enzyme, respectively (Smith et al., 2000); and is considered a rate-limiting 
step in the biosynthesis of PG (Sirois et al., 2004). Conversion of PGH2 into the different 
biological forms of PG is catalyzed by cell-specific terminal synthases (Flores and Barlund, 
2009). For instance, PGES and PGFS synthesize PGE2 and PGF2 , respectively, whereas 
prostaglandin dehydrogenase catabolizes PGF2  into 13, 14-dihydro-15-keto PGF2  (PGFM) 
(Tai et al., 2002).  
Although PG have a lipid nature, at physiological pH they behave as organic anions and do 
not diffuse easily across cellular plasma membranes (Shuster, 1998). Instead, PG utilize carrier-
mediated transport that includes three aspects: transport and metabolic clearance by the lung, 
transport by non-lung tissues that metabolize PGs, and transport by tissues that do not 
metabolize PGs (Shuster, 1998). Recently, PG transporter (PGT) in ovine endometrium was 
cloned and characterized, and its participation in PGF2 -induced luteolysis was demonstrated 
(Banu et al., 2008). Inhibition of PGT-mediated transport of PGF2  from the uterus prevented 
luteolysis and extended lifespan of the CL and length of the estrous cycle. Moreover, inhibition 
of PGT reduced the ability of the endometrium to secrete PGF2  in response to oxytocin (Banu 
et al., 2008). Apparently, ERK1/2 pathways modulate efflux of PGF2 , whereas JNK/SAPK 
pathways regulate both efflux and influx of PGF2  in ovine endometrial cells (Banu et al., 
2008). In ovine CL, expression of both PGT mRNA and protein was greater on d 7 to 21 than 1 
to 6 of the estrous cycle with maximal expression values on d 13 to 15 (Arosh et al., 2003). 






Characteristics, variants, and localization of PGF2  receptor  
PGF2  induces changes in intracellular functions by binding to a specific cellular membrane 
receptor that was cloned and characterized in several mammalian species (Abramovitz et al., 
1994; Graves et al., 1994; Kitanaka et al., 1994; Lake et al., 1994; Sakamoto et al., 1994). FP 
belongs to the family of G-protein-coupled receptors that, once activated, couples to Gq to 
trigger the inositol trisphosphate (IP3) second-messenger pathway. In cattle and sheep, FP 
protein has 362 amino acids, while human being and rat have 359 and 366, respectively. 
Molecular weight of FP is similar among species, varying between 40060 and 40983 in human 
beings and ruminants (Abramovitz et al., 1994; Graves et al., 1994; Kitanaka et al., 1994; 
Sakamoto et al., 1994).  
Two FP isoforms have been identified in the sheep CL (Graves et al., 1994; Pierce et al., 
1997). Both FPA and FPB have similar amino acid (AA) sequences through the seven 
transmembrane domains, but differ in the carboxyl terminus site, in which FPA has 45 more 
AA than FPB (Pierce et al., 1997). Thus, FPB isoform is a truncated version of the FPA 
isoform. Activation of FP receptor variants leads to an increase in inositol phosphate 
accumulation, protein kinase C (PKC) activation, and intracellular calcium release consistent 
with activation of G-proteins of the Gq family (Abramovitz et al., 1994; Graves et al., 1994; 
Sakamoto et al., 1994). However, FPA and FPB activation led to Rho-dependent changes in 
cell morphology, formation of actin stress fibers, and tyrosine phosphorylation of p125 FAK 





In cells transfected with either FPA or FPB, PGF2  elicited a similar maximum IP 
accumulation; nevertheless, basal accumulation of IP was about 130% greater in cells 
expressing FPA than in those expressing FPB isoforms (Pierce et al., 1997). Moreover, FP 
isoforms are regulated differentially by PKC. In human embryonic kidney cells that steadily 
expressed FPA and FPB, PKC inhibited PGF2 -stimulated IP formation by FPA but not by FPB 
(Fujino et al., 2000a). Also, a stronger PKC-mediated agonist dependent phosphorylation was 
observed in FPA, but not in FPB (Fujino et al., 2000a), indicating that under conditions of acute 
activation or down-regulation of PKC, the FPA isoform might be more responsive to 
submaximally  stimulating concentrations of agonist than the FPB variant. In addition, agonist-
induced stimulation of inositol phosphate formation, and mobilization of intracellular Ca
2+
 
indicate that the FPB variant resensitizes more slowly than the FPA (Fujino et al., 2000b). 
Apparently, the carboxyl terminus of the FPA isoform is critical for resensitization because the 
absence of 45 of 46 AA in the carboxyl terminus of FPB slowed resensitization and prolonged 
signaling (Fujino et al., 2000b). Overall, these findings demonstrated molecular and signaling 
differences between variants of FP that may contribute to elucidation of physiological actions 
of PGF2  in the CL. Possibly, differential expression of the two isoforms in response to 
functional stages of the CL may alter intracellular responsiveness to PGF2  (Hoyer, 1998). 
In ovine CL, northern blot analysis revealed similar expression of FP mRNA at mid-luteal 
phase (d 10, 2.73 ± 0.17; d 12 2.47 ± 0.91) but greater on d 16 of pregnancy (Rueda et al., 
1995b). A subsequent study corroborated that concentrations of FP mRNA did not vary 
throughout the estrous cycle (Juengel et al., 1996), although a significant reduction in FP 





(Tsai et al., 1998a) during PGF2 -induced luteolysis in sheep, cow and pig (Rueda et al., 1995b; 
Sakamoto et al., 1995; Estill et al., 1995; Mamluk et al., 1998). These findings are consistent 
with the reduction of number of FP by the time of luteolysis (Wiepz et al., 1992), and the 
decline of FP mRNA concentration in cultured LLC treated with a PKC activator or calcium 
ionophore (Tsai et al., 2001). Thus, reduction of FP protein and mRNA concentrations were 
associated with significantly lower concentrations of P4 and luteal weight (Juengel et al., 1996; 
Tsai et al., 1998a). On the basis of the previous evidence, FP seems to be downregulated by a 
mechanism of homologous ligand that could imply reduction of mRNA FP expression for 
PGF2  at the same time that FP are downregulated by mechanisms of receptor internalization 
and degradation (Tsai et al., 1998a). 
Both FP mRNA and protein are considerably more abundant in luteal tissue than in any 
other ovine tissue (Tsai et al., 1998a). Amounts of FP mRNA and proteins were approximately 
26 and 148 times greater, respectively, in luteal tissue than in ovarian stroma, and this figure 
was even greater when compared with other tissues. FP were localized primarily in LLC from 
several mammalian species (Balapure et al., 1989; Gadsy et al., 1990; Juengel et al., 1996; 
Mamluk et al., 1998; Boonyaprakob et al., 2001; Bogan et al., 2008). Using separated 
populations of LLC and SLC purified by elutriation, high affinity binding sites (Kd = 19 to 64 
nM in pigs and 17.4 ± 2.3 nM in ewes) were identified exclusively in LLC, whereas low 
affinity binding sites (Kd = 262-3103 nM in pigs and 409 ± 166 nM in ewes) were present in 
LLC and SLC (Balapure et al., 1989; Gadsby et al., 1990). Number of high affinity PGF2 -
binding sites was low during the early luteal phase of the pig (before d 12) but increased 





allowed detection of FP mainly in LLC (Sakamoto et al., 1995). However, in a subsequent 
study using RT-PCR with elutriated SLC and LLC, FP mRNA was detected in both 
steroidogenic cells, although FP mRNA expression in LLC was around 2.5 times greater than 
in SLC (Mamluk et al., 1998). Immunohistochemical analysis (IHC) in primate CL revealed 
expression of FP protein in LLC and vascular endothelial cells (Bogan et al., 2008). Amounts 
of FP were lower during early and mid-luteal phase and increased in the following days of the 
menstrual cycle.  
Albeit evidence of FP in the vascular tissue of the CL has been controversial over the years, 
presence of FP in endothelial cells was documented in pigs, cows and primates (Mamluk et al., 
1998; Zannoni et al., 2007; Bogan et al., 2008). Using in situ hybridization, Boonyaprakob et 
al. (2003) did not identify FP in endothelial cells in pig CL. However, in a recent report, 
microvascular endothelial cells were isolated from porcine CL by an immunomagnetic 
separation protocol and FP protein and mRNA were identified and quantified by 
immunofluorescence and RT-PCR (Zanoni et al., 2007); FP mRNA and protein expression 
significantly increased from early- to mid-luteal phase, attaining maximum amounts during 
pregnancy. FP mRNA was identified in luteal endothelial cells from bovine CL (Mamluk et al., 
1998), whereas in primates FP in vascular tissue was identified by IHC (Bogan et al., 2008). 
Luteolysis is an intricate process in which substances locally produced by different cellular 
components modulate luteal regression by paracrine and autocrine mechanisms (Korzekwa et 
al., 2008). In luteal steroidogenic cells cultured in monolayer, PGF2  increased P4 
accumulation after 24 h incubation. Nevertheless, PGF2  reduced production of P4 in culture of 





among different cellular components appear to be necessary so that synthesis and secretion of 
P4 is disrupted, and hence, subsequent steps of luteolysis take place. In addition, two important 
vasoactive factors, NO and END1, produced by endothelial cells (Girsh et al., 1996a; 
Skarzynski et al., 2003) appear to be involved in luteolysis. Moreover, they are regulated by 
PGF2  (Manluk et al., 1999; Skarzynski et al., 2003; Shirasuna et al., 2008), and PGF2  itself is 
involved in regulating blood flow in extraovarian tissues (Ogletree et al., 1982). Hence, 
presence of FP in endothelial cells is consistent with experimental evidence about the role of 
luteal vascular tissue in luteolysis.  
Signal transduction pathways involved in PGF2 -mediated luteolysis 
Activation of luteal FP by PGF2  during luteolysis modifies the molecular conformation of 
the receptor allowing activation of G protein (Alberts et al., 2002). G protein (GTP-binding 
protein) is a trimeric molecule composed of three subunits, , , and , which remain inactive 
while receptor is not bound to its ligand. Once G-protein is stimulated, GDP in the  subunit is 
exchanged by GTP, and as a consequence, the trimeric G-protein dissociates into two activated 
components,  subunit and  complex (Levitzki, 1987). In Gq-protein-coupled receptors, as is 
the case of FP, activated  subunit triggers the inositol phosphate (IP3) second-messenger 
pathway. Briefly,  subunit activates the enzyme phospholipase C (PLC), which cleaves 
phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] into two molecules, inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG) (Berridge et al., 1983; Davis et al., 1987; Davis et 
al., 1988). Both molecules act as intracellular messengers with different functions (Berridge et 





endoplasmic reticulum (ER). In the ER membrane, IP3 binds and opens IP3-gated Ca
2+
-release 
channels increasing concentrations of intracellular Ca
2+ 
(Streb et al., 1984; Spat et al., 1986; 
Davis et al., 1987a; Williamson and Monk, 1989). In the cellular membrane, DAG together 
with the increased cytosolic Ca
2+
 activates the enzyme protein kinase C (PKC) (Berridge et al., 
1987). The PKC, via mitogen-activated protein kinase (MAP kinase) activates PLA, which in 
turn stimulates release of AA from the membrane (Qiu and Leslie, 1994; Chen et al., 1998) and 
promotes synthesis of PGF2 . Thus, uterine PGF2  induces synthesis of luteal PGF2 . 
Recently, it was demonstrated that the interaction of PGF2  with FP receptor activates an 
additional intracellular signaling pathway, the mitogen activated protein kinases (MAPKs), that 
is involved in the transduction of extracellular signals into the nucleus to regulate gene 
expression (Chen et al., 1998). This pathway has been widely described in the signaling of 
receptor-linked tyrosine kinases activated by several growth factors, and involves 
phosphorylation of numerous serine/threonine-selective protein kinases, such as RAF, MEK 
and MAPK, that regulate the activities of several transcription factors (Alberts et al., 2002). 
Apparently, the RAF/MEK/MAPK signaling cascade also mediates the cellular response to 
various ligands that bind G protein-coupled receptors, including PGF2  (Chen et al., 1998; Tai 
et al., 2001; Hou et al., 2008). Three isoforms of Raf family were detected in the bovine CL, 
but only Raf-1 and B-Raf were activated by PGF2  and phorbol 12-mysristate 13-acetate 





kinases were activated. Activation of this protein kinase pathway by PGF2  may represent a 
mechanism by which the intracellular signal initiated by FP is transmitted to the nucleus to 





via MEK/ERK signaling pathway, stimulated mRNA and protein expression of early growth 
response 1 (EGR1) both in vivo and in vitro (Hou et al., 2008). EGR1 has been associated to 
various reproductive functions (Espey et al., 2000; Russell et al., 2003). During PGF2 -
stimulated luteal regression in cow, EGR1 induced expression of TGF 1, an important tissue 
remodeling protein also involved in apoptosis (Hou et al., 2008).  
The first attempts to understand the intracellular mechanisms by which PGF2  disrupts 
synthesis and secretion of P4 were carried out in rat luteal cells. Treatment of rats with PGF2  
down-regulated LH luteal receptors within 12-24 h in parallel with the decrease of P4; 
nevertheless, reduction of P4 concentrations preceded a decrease in LH receptors by several 
hours (Grinwich et al., 1976). Also, it was demonstrated that LH or PGF2  in absence of LH, 
stimulated P4 production in a dose dependent manner in dissociated luteal cells (Thomas et al., 
1978). In addition, LH induced a significant increase of adenylate cyclase activity and 
accumulation of cAMP; whereas adding PGF2  to LH-supplemented cultured luteal cells 
reduced both adenylate cyclase activity and cAMP accumulation by about 50 to 70% (Thomas 
et al., 1978; Dorflinger et al., 1983; Kenny and Robinson, 1986). Moreover, addition of 
dibutyryl cyclic AMP (dbcAMP; analogue of cAMP) reversed PGF2 -induced inhibition of P4 
(Thomas et al., 1978; Dorflinger et al., 1983 Kenny and Robinson, 1986).  
From these early studies, it was evident that the PGF2 -induced block of LH-stimulated P4 
secretion was not due to inhibition of specific binding activity of LH receptor, cAMP 
degradation, direct action on adenylate cyclase or direct damage of luteal cells by PGF2  





inhibition of LH-stimulated P4 may be due to inhibition of activation of cAMP accumulation by 
LH and inhibition of luteal cell response to cAMP (Thomas et al., 1978; Dorflinger et al., 
1983). However, when dbcAMP or LH was added to dispersed luteal cells from rats treated 
with PGF2  in vivo, P4 production was reduced significantly, indicating that PGF2 -induced 
inhibition of P4 production may occur at a site beyond cAMP formation in the steroidogenic 
pathway (Jordan, 1981). Because PGF2  was more effective to inhibit dbcAMP-stimulated 
steroidogenesis in vivo (Jordan, 1981) than in vitro (Thomas et al., 1978; Jordan, 1981) it was 
suggested that PGF2 -induced inhibition of P4 may be the result of both direct and indirect 
effects (Jordan, 1981). In addition, PGF2  was able to inhibit activity of 3 -HDS and 
cholesterol esterase (Dwyer and Church, 1979), as well luteal adenylate cyclase activity 
concomitant with the decrease of P4 concentrations in a 24-h period (Agudo and Smith, 1982). 
Thus, on the basis of the experimental evidence it was likely that PGF2  may have multiple 
sites of action and that its luteolytic actions involve other substances or mediators, indicating 
the complex mechanism of luteolysis.  
Luteal regression was associated to structural changes in cellular membranes (Carlson et al., 
1984) and hydrolysis of phosphoinositides with the concomitant increment of radiolabeled 
inositol phosphates (Raymond et al., 1983; Leung et al., 1986). At that time, increasing 
evidence from other tissues strengthened the idea that inositol polyphosphates may function as 
a second messenger for mobilizing Ca
2+
 from intracellular stores (Burguess et al., 1984); and 
this mechanism may be responsible for inhibition of gonadotropin-induced cAMP and 
progesterone production (Leung et al., 1986; Davis et al., 1987). In this regard, incubation of 
luteal cells in Ca
2+







 ionophore A23187 inhibited LH-stimulated cAMP accumulation in a dose-dependent 
manner, although the inhibition was dependent on presence of extracellular Ca
2+
 (Dorflinger et 
al., 1984). In addition, Ca
2+
 directly inhibited LH-sensitive adenylate cyclase activity at 
concentrations consistent with known (IC50, ~ 10 M) intracellular values (Dorflinger et al., 
1984). Moreover, the inhibitory effect of Ca
2+
 was not due to stimulation of an increase in 
cAMP degradation because inhibition occurred in cells incubated in presence or absence of a 
cAMP phosphodiesterase inhibitor (Dorflinger et al., 1984). On the other hand, the effect of 
PGF2  on LH-stimulated cAMP accumulation was independent of the presence of Ca
2+
 in the 
medium, and the blockade of Ca
2+
 channels by verapimil did not affect the magnitude of 
inhibition induced by PGF2  as well. Thus, it appeared that the luteolytic effect of PGF2  was 
not dependent on an influx of extracellular Ca
2+
, instead, it seemed to be dependent on an 
increase in intracellular Ca
2+
 by other means (Dorflinger et al., 1984; Davis et al., 1987).  
In bovine luteal cells, PGF2  increased turnover of inositol phospholipid inducing a rapid (10 
sec) and sustained (up to 60 min) increment in the concentrations of inositol phosphates (IP), 
that was greater in magnitude in IP3 than IP2 and IP1 and independent of extracellular Ca
2+
 
(Davis et al., 1987a; Davis et al., 1988). Also, PGF2  augmented concentrations of Ca
2+
 by 2 to 
3 fold, again independent of extracellular Ca
2+
. In cultured SLC, removal of Ca
2+
 from the 
medium reduced hormone-stimulated but not basal P4 production, whereas in LLC both basal 
and stimulated P4 production were dependent on Ca
2+
 (Alila et al., 1990). Interestingly, the 
finding that LH was able to enhance accumulation of cAMP as well concentrations of IP3 and 
Ca
2+
 in bovine luteal cells indicated that LH actions are mediated by at least two second 





the same second messenger systems to produce opposite effects on P4 production by luteal 
steroidogenic cells (Wiltbank et al., 1991).  
Measurements of free intracellular Ca
2+
 in ovine individual SLC and LLC demonstrated 
differential response of both cell types to PGF2  and calcium ionophore (A23187). Although 
A23187 increased free intracellular Ca
2+
 in the two cell types, SLC underwent an abrupt and 
marked increase in free Ca
2+
 that was highest by 30 s and gradually returned to baseline in the 
time course of 3 min. Instead, LLC reached the greatest free Ca
2+
 by 90 s and required more 
than 30 min to return to baseline values (Wiltbank et al., 1989a). In addition, PGF2  induced a 
remarkable increase of intracellular Ca
2+
 in LLC but not in SLC; whereas LH did not affect free 
Ca
2+
 concentration in either luteal cell type (Wiltbank et al., 1989a). The increment of 
intracellular Ca
2+
 in PGF2 -stimulated LLC was dependent upon influx of extracellular Ca
2+
, 
because inclusion of a Ca
2+
 channel blocker decreased and removal of extracellular Ca
2+
 
eliminated the response to PGF2  (Wiltbank et al., 1989a).  
At this point, it is clear that the IP3 increase after FP activation by PGF2  is associated to an 
abrupt and transient increment of intracellular Ca
2+
 released from endoplasmic reticulum, in 
whose membrane IP3 binds specific receptors (Vermassen et al., 2004). Nevertheless, other 
intracellular organelles, such as the Golgi apparatus and secretory vesicles, may act as IP3-
sensitive Ca
2+
 stores (Vermassen et al., 2004). The IP3 receptor has been characterized as a 
tetrameric intracellular ligand-gated Ca
2+
 channel (250-300 kDa), bearing a large cytosolic 
domain in which several regulatory molecules can bind, including IP3 and Ca
2+
, and 





are encoded by different genes and determine three IP3 receptor isoforms (types 1, 2 and 3) 
(Südhof et al., 1991; Blondel et al., 1993; Yamada et al., 1994; Yamamoto et al., 1994). The 
structure of the type 1 IP3 receptor has been better characterized and consists of a ligand-
binding domain in the NH2 terminal portion, a coupling or modulatory domain in the middle 
portion and a Ca
2+
 channel domain in the COOH-terminal portion (Mignery and Südhof, 1990). 
The three IP3 receptor isoforms were identified in mouse granulosal cells (Díaz-Muñoz et al., 
2008); but only IP3 receptor type 2 was observed in granulosal and thecal cells of growing 
follicles and luteal cells of developing CL in pigs (Steffl et al., 2004).  
As indicated above, protein kinase C (PKC) is associated to PGF2 -induced inhibition of P4 
production by luteal steroidogenic cells (Wiltbank et al., 1991). In ovine luteal cells, activity of 
PKC was 4 times greater in LLC than SLC. Activation of PKC by phorbol 12-myristate 13-
acetate (PMA) caused an abrupt and dose-dependent inhibition of P4 production in LLC and 
LH-, forskolin- and dbcAMP-stimulated SLC (Wiltbank et al., 1989b). Moreover, PMA 
reduced P4 production in LLC treated with 25-hydroxycholesterol but that effect was not 
demonstrated in LH-stimulated SLC. Apparently, the inhibitory action of PKC in SLC occurs 
after LH binding and cAMP production because in forskolin-, dbaAMP- and LH-stimulated 
cells, SLC P4 production was similarly inhibited. It is likely that PKC inhibition occurs prior to 
enzymatic cleavage of cholesterol because inclusion of 25-hydroxycholesterol in the culture 
medium did not affect P4 production by SLC in response to PMA (Wiltbank et al., 1989b). The 
presence of lipoproteins in the culture medium increased P4 production in both LLC and LH-
stimulated SLC with a greater effect of high density lipoproteins (HDL) than low density 





in the absence of HDL or LDL; whereas in SLC stimulated or not with LH and/or HDL or 
LDL, PGF2  did not reduce P4 production (Wiltbank et al., 1990). To further demonstrate if 
PKC was mediating the inhibition of P4 by PGF2 , PKC-deficient or normal LLC stimulated 
with LDL or HDL were cultured in presence or absence of PGF2 . As was expected, PGF2  
reduced P4 production in PKC-normal LLC with LDL or HDL, but had no effect in PKC-
deficient LLC (Wiltbank et al., 1990).  
It seems to be evident that PKC mediates the antisteroidogenic actions of PGF2  in luteal 
cells; nevertheless, the locus at which PKC blocks P4 production in LLC and SLC is apparently 
different. Consistent with the differences in the IP3−Ca
2+
−PKC second messenger system 
indicated above, SLC and LLC have other morphological and functional differences. For 
instance, Fitz et al. (1982) reported that SLC in the ewe had 11 times greater LH receptors than 
LLC (33260 and 3074 for SLC and LLC, respectively), whereas LLC contained 32 times 
greater PGF2  receptors than SLC (62143 and 2115 for LLC and SLC, respectively). In 
contrast, a later study in sheep from the same group indicated no differences in the number of 
LH receptors between both types of steroidogenic cells during the mid-luteal phase (Harrison et 
al., 1987). Although SLC were considerably more responsive to LH stimulus, LLC produced 6 
to 8 times more P4 than SLC (Ursely and Leymarie, 1979; Harrison et al., 1987). Moreover, 
pharmacological or physiological activation of the cAMP second messenger pathway did not 
increase P4 production by LLC (Hoyer and Niswender, 1984). It was suggested that this 
signaling pathway is constitutively activated in these steroidogenic cells and for that reason 
stimulation of LLC with LH did not cause a further increment in P4 output (Hoyer and 





From the numerous PKC isoenzymes described in the literature, five forms, , I, II, , and 
 were detected in bovine luteal tissue (Sen et al., 2004). Whereas , I, II variants were 
detected in both luteal steroidogenic and endothelial cells, PKC  was located exclusively in 
steroidogenic cells of the CL (Sen et al., 2006). PKC II and PKC  were expressed more in day-
10 than day-4 CL (Sen et al., 2004). In addition, PGF2  induced a significantly lower increase 
in intracellular Ca
2+
 concentration in 4-day than 10-day CL in both LLC and SLC (Sen et al., 
2005; Choudhary et al., 2005). A PKC  inhibitor reduced the PGF2 -induced calcium increase 
in both LLC and SLC on day 10 (Sen et al., 2005). The magnitude of P4 reduction induced by a 
pharmacological increase of Ca
2+
 concentrations was lower in day-10 than day-4 CL 
(Goravanahally et al., 2007). Moreover, down-regulation of PKC  expression by siRNA 
technology or blocking PKC  activation reduced the effectiveness of PGF2  in reducing LH-
stimulated production of P4 (Sen et al., 2005; Goravanahally et al., 2007). Hence, these findings 
strongly indicate that differential expression of certain components associated to signal 
transduction triggered by PGF2  may account for lack of responsiveness of CL during early 
development. Previously it was demonstrated that the insensibility of early CL to PGF2  was 
not due to the lack of FP (Wiltbank et al., 1995; Mamluk et al., 1999), or limited capacity of 
PGF2  to stimulate END1 (Choudhary et al., 2004; Choudhary et al., 2005) as had been 
suggested (Levi et al., 2000). Instead, a lower expression of PGT and a greater PGE2 
production in the early CL may contribute to explain its resistance to luteolytic actions of 
PGF2  (Arosh et al., 2004). However, new findings about differential expression of signaling 





Luteal PGF2  and luteolysis: a proposed model to explain the intraluteal mechanism that 
regulates luteal regression in ruminants 
As indicated elsewhere (Diaz et al., 2002; Wiltbank and Ottobre, 2003; Niswender et al., 
2007), the corpus luteum of several mammalian species has the capacity to synthesize PGF2 . 
Luteal PGF2  is synthesized and secreted by LLC, and by autocrine and paracrine mechanisms 
this hormone coordinates and participates in the successive intracellular and intercellular events 
that are conducive to the functional and structural disappearance of the CL. In the bovine CL, 
LLC have the molecular and metabolic machinery related with the synthesis, transport, and 
signaling of both PGF2  and PGE2 (Arosh et al., 2004). For instance, Cox-2, PGES, PGT, EP2, 
EP3 and FP were greatly regulated, whereas Cox-1, PGFS and PGDH were expressed 
uniformly throughout the luteal lifespan. Accordingly, synthesis of PG during the bovine 
estrous cycle is directed selectively toward PGE2 in early luteal phase and toward PGF2  during 
luteal regression, but it is nonselective during mid-luteal phase (Arosh et al., 2004). Likewise, 
in sheep, exogenous PGF2  induced expression of Cox-2 but not Cox-1; Cox-2 mRNA 
expression increased about 10 fold in less than 1 h after PGF2  was added to cultured LLC 
(Tsai and Wiltbank, 1997). Also, Cox-2 mRNA was greater expressed in LLC than SLC (4507 
vs 323 copies/cell). These findings indicate that LLC respond to uterine PGF2  by increasing 
synthesis of luteal PGF2  within 1 h or less, and in that way intraluteal PGF2  signal is 
amplified several times by a positive feedback loop (Tsai and Wiltbank, 1997), in which luteal 
oxytocin and other mediators may be involved (Townson and Pate, 1994; 1996; Mann, 1999; 





The importance of intraluteal production of PGF2  during luteolysis was demonstrated by 
applying a different experimental approach (Niswender et al., 2007). On day 10 of the ovine 
estrous cycle, an implant with 0, 1 or 10 mg of indomethacin (inhibitor of PG synthesis) was 
delivered into the CL. Progesterone production was significantly greater on days 13 through 16 
of the cycle and CL were heavier in indomethacin(10 mg)-treated than in control ewes 
(Niswender et al., 2007). Thus, it seems that luteal PGF2  is required in both functional 
(decreasing steroidogenic capacity) and structural (inducing apoptosis and tissue degradation) 
phases of luteolysis.  
Recently, Niswender et al. (2007) proposed a model to explain the intraluteal mechanism 
that regulates luteal regression in ruminants. In this model, the authors suggested that although 
luteolysis is initiated from extra-luteal influence (endometrial PGF2 ), the mechanisms that 
ultimately lead to the demise of the CL are orchestrated by the corpus luteum itself through 
autocrine and paracrine actions of luteal PGF2  and oxytocin. Thus, once the uterine signal 
initiates luteal regression, increased luteal secretion of PGF2  triggers mobilization of 
intracellular Ca
2+
 in large luteal cells and secretion of oxytocin by these cells. Oxytocin in turn, 
increases concentrations of Ca
2+
 in small luteal cells. Apoptosis follows Ca
2+
 mobilization in 
both cell types. Likewise, as was indicated elsewhere in this review, several other factors 
secreted from nonsteroidogenic cells of luteal origin (vascular smooth muscular cells, 
endothelial cells, and immune cells) interact with steroidogenic cells to support luteolytic 






































































Endothelin system: a modulator of ovarian function 
Ovarian function is regulated mainly by the pituitary gonadotropins, follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH), through their receptors. However, numerous 
factors such as steroid hormones, peptides and growth factors, produced locally or not, play 
essential modulatory roles in follicular and luteal function (Tisdall et al., 1995; Schams and 
Berisha, 2002; Webb et al., 2002; Lopez et al., 2005). 
Endothelins (END), a family of 21-amino acid peptides constituted by three different 
isoforms (END1, END2 and END3), are involved in a wide variety of biological functions in 
diverse tissues (Kedezierski and Yanagisawa, 2001). The most relevant END family member 
associated with female reproductive function, END1, has been identified in the ovary of several 
mammalian species (Usuki et al., 1991; Iwai et al., 1991; Flores et al., 1992; Kamada et al., 
1993; Tedeschi et al., 1994; Mancina et al., 1997; Flores et al., 2000; Hinckley and Milvae, 
2001; Schams et al., 2003; Boiti et al., 2005).  
In the corpus luteum, END1 plays an important role in mediating PGF2 -induced luteal 
regression. END1 reduced both basal and LH-stimulated progesterone secretion in a dose-
dependent manner, and its inhibitory effect was prevented by the addition of a selective 
ENDRA receptor antagonist (Girsh et al., 1996a; Hinckley and Milvae, 2001; Doerr et al., 
2008). In antral follicles, END1 acts as a modulator of the steroidogenic function of granulosal 
cells. Both LH- and FSH-stimulated progesterone and cAMP production in granulosal cells 
were suppressed by END1 in a dose-dependent manner (Iwai et al., 1991; Flores et al., 1992; 





and paracrine mechanisms, inhibits the luteinization of granulosal cells until near time to 
ovulate, when its activity is abolished and all events conducive to ovulation take place. 
Brief description of endothelin system 
The endothelin system consists of a group of peptides (ligands) and proteins (enzymes and 
receptors) involved in a wide variety of physiologic and pathologic roles in numerous 
mammalian tissues (Nussdorfer et al., 1999; Kedezierski and Yanagisawa, 2001). These 
molecules have been described as two G-protein-coupled receptors, three peptide ligands, and 
two activating peptidases (Pinet et al., 2004).  
Endothelin-1 (END1), a peptide constituted of 21 amino acids, originally was isolated from 
porcine aortic endothelial cells as a potent vasoconstrictor (Yanagisawa et al., 1988). 
Endothelin-2 (END2) and endothelin-3 (END3) were discovered later and constitute two 
structurally-related peptides that differ from END1 by two and six amino acids, respectively 
(Fig. 3; Inoue et al., 1989). Endothelins are synthesized as large molecules (~200 amino acids) 
named preproendothelins (ppEND), which are cleaved into three physiologically active 
endothelin peptides (Fig. 4) through two consecutive enzymatic steps (Rubanyi and Polokoff, 
1994). The first step involves a furin-like protease that converts pp-ENDs into an inactive END 
precursor (p-ENDs; ~37 to 41 amino acids). The second step is performed by a specific 
endopeptidase (zinc metalloendoeptidase) known as endothelin-converting enzyme (ECE), 

























Figure 3. Molecular structure of endothelin peptides. The unshaded circles illustrate the 
variable amino acid sequence of human endothelins showing the amino acid substitution of 
END2 and END3 with respect to END1 (Modified from Nussdorfer et al., 1999). Each END 
peptide is encoded by a different gene. The three genes have different chromosomal 
localization and are differentially regulated. END isoforms are molecularly similar to 
cardiotoxic peptides isolated from the venom of Atractacpis engaddensis. 
Two membrane receptors (ENDRA and ENDRB) have been identified as responsible for the 
intracellular signals that cause the different biological effects of ENDs described in the 
scientific literature (reviewed by Nussdorfer et al., 1999 and Kedezierski and Yanagisawa, 
2001). ENDRA has a very high affinity for END1 and END2 and around 70 to 100% lower 
affinity for END3, while ENDRB binds with high and similar affinity to all three END 






























































Figure 4. Molecular components of endothelin pathway (Modified from Pinet et al., 2004). 
Although END1 was described originally as a potent vasoconstrictor, currently innumerable 
biological effects of this peptide family are known in a wide variety of tissue, taking part not 
only in physiological but also in pathological functions in human beings and animals. ENDRA 
receptor has around 100 fold more affinity for END1 and END2 than END3, while ENDRB 
receptor interacts on a non-selective manner with three END peptides.   
Molecular characteristics of endothelin receptor type A 
Endothelin receptors have been isolated and cloned from mammalian tissues and the 
structures of the mature receptors have been deduced from the nucleotide sequences of the 
cDNA (Arai et al., 1990; Sakurai et al., 1990). ENDRA structure is consistent with a seven-
transmembrane domain (7TM), G protein-coupled receptor belonging to the rhodopsin-type 
receptor family. Binding of END to ENDRA and ENDRB activate at least three classes of G  
proteins (G s, G 1 and G q) (Miyauchi and Masaki, 1999). ENDRA has an extracellular NH2-























domain. The transmembrane domains consist of seven amphipathic membrane-spanning helices 
joined together by three intracellular and three extracellular loops. The ENDRA receptor has an 
N-terminal signal sequence with a relatively long extracellular N-terminal portion preceding 
the first transmembrane domain (Figure 5). There are two separate ligand-interaction sub-
domains, and the extracellular loops, particularly between transmembrane domains 4 to 6, 


















Figure 5. Structure of endothelin receptor type A 
Activation of ENDRA receptors produces a range of biological effects in different tissues. 
END1 is known as one of the most potent vasoconstrictors. In the ovary of Chinese hamster, 
for example, END1 through ENDRA receptor induces the release of arachidonic acid (AA) 
from the cell membrane (Trevesi et al., 2002). END1-induced vascular contraction is 
accompanied by an increase in calcium (Ca
2+
) through its mobilization from intracellular stores 
and as result of transmembrane Ca
2+
 influx. Also, extracellular Ca
2+





in END1-induced arachidonic acid (AA) release from membrane lipids by activating ENDRA 
receptor. In the ovary of hamsters, AA was released by activating two types of Ca
2+ 
permeable 
nonselective cation channels and a store-operated Ca
2+
 channel, which were activated by Gq 
and G12 proteins coupled to ENDRA receptor (Kawanabe et al., 2003).   
Binding of END1 to ENDRA changes its conformation and alters the conformation of the G 
protein bound to the receptor. The alteration of  subunit of the G protein allows it to exchange 
its GDP for GTP and causes the G protein to break up into two active components,  subunit 
and  complex. Immediately  subunit or  complex activates phospholipase C (PLC) and 
the IP3 and DAG pathway (Trevisi et al., 2002) described above for PGF2 . Alternatively, in 
human vascular endothelium, PKC and non- receptor protein tyrosine kinase (PTK) activated 
by END1 through its receptor ENDRA, regulate the expression of endothelial nitric oxide 
synthase (eNOS) at the genomic level and stimulate NO production (Marsen et al., 1999). 
In addition, in various cell types, ENDRA receptors activate PLC to produce IP3 as well as 
DAG. The IP3 stimulates release of Ca
2+
 from IP3-sensitive stores (endoplasmic reticulum) and 
subsequent activation of store-operated Ca
2+
 channels. After or concomitant with the release of 
Ca
2+
 from intracellular stores, a second phase is initiated in which Ca
2+
 moves into the cell 
from the extracellular compartment. The resulting Ca
2+
 influx is responsible for an additional 







Role of END1 in follicular function  
END family members have been identified in ovarian antral follicles from pig (Iwai et al., 
1991; Kamada et al., 1993; Flores et al., 1995; Flores, 2000), rat (Iwai et al., 1993; Tedeschi et 
al., 1994), cow (Acosta et al., 1998; Levy et al., 2003) and human being (Magini et al., 1996; 
Mancina et al., 1997). Their general role appears to be to regulate steroid production by 
granulosal and thecal cells of antral follicles (Iwai et al., 1991; Tedeschi et al., 1992; Flores et 
al., 1992; Kamada et al., 1993) by acting as a local modulator of ovarian function.  
Measurable amounts of END1 (Iwai et al., 1991) were lower in porcine follicular fluid of 
small (1 to 2 mm) than medium (3 to 5 mm) or large (6 to 11 mm) follicles (9.4 ± 1.1 vs 12.2 ± 
1.1 b and 14.2 ± 1.8 pg/ml, respectively; P<0.05); and greater in porcine granulosal cells 
cultured with LH than FSH (56 ± 9.3 and 4.9 ± 1.8 pg/106 cells × h, respectively) (Iwai et al., 
1991). Also, cultured porcine granulosal cells collected from large antral follicles (9 to 10 mm) 
had three fold greater (P<0.05) binding capacity for END1 than granulosal cells from small 
follicles (2 to 5 mm; Flores et al., 1995). Studies in porcine ovaries have demonstrated that 
greater binding capacity for END1 (Flores et al., 1995) and higher immunoreactivity of END1 
(Flores, 2000) were restricted to vascular and granulosal cell compartments of antral follicles. 
END1 gene expression in ovarian follicles started around the antral stage; it increased as 
follicles developed toward the periovulatory stage, and it decreased immediately after ovulation 
(Flores, 2000). Likewise, large antral follicles expressed higher immunoreactivity to END1 






Multiple evidence has indicated that END can modulate steroidogenic function of GC in 
several mammalian species (Iwai et al., 1991; Kamada et al., 1992; Flores et al., 1992; 
Tedeschi et al., 1992; Kamada et al., 1993; Tedeschi et al., 1994; Magini et al., 1996; Calogero 
et al., 1998; Plonowski et al., 1999; Denkova et al., 2000; Denkova et al., 2002; Yaneva et al., 
2003). Significantly less LH- (Iwai et al., 1991), hCG- (Kamada et al., 1993) and FSH-
stimulated (Flores et al., 1992; Kamada et al., 1993) accumulation of progesterone was 
quantified in GC cultured in presence of END1. Both FSH- and LH-stimulated progesterone 
accumulation decreased in a dose-dependent manner (Iwai et al., 1991; Kamada et al., 1993). 
Similarly, LH- and FSH-stimulated cAMP production in granulosal cells was suppressed by 
END1 in a dose-dependent manner (Iwai et al., 1991; Flores et al., 1992; Flores et al., 1999). 
The cellular mechanism by which END1 reduced the FSH-stimulated progesterone production 
in the rat, could be by inhibiting some progesterone-forming enzymes (Flores et al., 1999) 
and/or by stimulating progesterone-degrading enzymes (Tedeschi et al., 1992). This mechanism 
would imply the activation of phosphoinositide-calcium-PKC pathway and the obstruction of 
FSH-stimulated steroidogenesis by inhibiting cAMP production (Flores et al., 1999). 
Three END isoforms had similar inhibitory effects on progesterone production by porcine 
(Iwai et al., 1991; Kamada et al., 1993) and murine (Tedeschi et al., 1994) granulosal cells. 
Therefore, it has been suggested that the nonselective receptor, ENDRB, could be involved in 
that action (Iwai et al., 1991; Tedeschi et al., 1994). Iwai et al. (1993) documented the presence 
of abundant ENDRB mRNA on granulosal cells of developing follicles in rat. However, 
competitive binding assays and receptor agonist competition experiments, performed in 





porcine ovary (Flores et al., 1995). The latter authors suggested that such divergences could be 
attributed to different methodologies and species used in these studies.   
Role of END1 in luteolysis 
Prostaglandin F2  has been documented as the main luteolytic factor in many mammalian 
species (Niswender et al., 2000). However, it is currently known that numerous other factors 
participate in luteolysis (McCracken et al., 1999), some of which act in a paracrine or/and 
autocrine manner (Girsh et al., 1996a; Shirasuna et al., 2006). PGF2  suppressed the P4 
secretion from large luteal cells only in the presence of endothelial cells, so Girsh et al. (1995) 
suggested that one or more factors produced in the microvascular tissue of the CL could be 
involved in that process. At that time, END1 was proposed as a possible mediator in PGF2 -
induced luteal regression, and subsequent evidence corroborated that hypothesis (Girsh et al., 
1996a; Miyamoto et al., 1997; Doerr et al., 2008). 
Studies in ruminants confirmed that END1 reduces both basal and LH-stimulated P4 
secretion in a dose-dependent manner (Girsh et al., 1996a; Hinckley and Milvae, 2001), and 
that the inhibitory effect could be prevented by the addition of a selective ENDRA receptor 
antagonist (Girsh et al., 1996a; Doerr et al., 2008). Apparently, END1 is synthesized and 
secreted only by vascular endothelial cells, because END1 could not be detected in either 
luteal-like cells or luteal cell extract (Girsh et al., 1996a). On the other hand, a significantly 
greater content of ENDRA and expression of END1 mRNA were detected in CL collected on 
day 18 of the bovine estrous cycle compared with those  collected on day 5 and 10 of the cycle 





expression were observed at middle (days 7 to 12) and late (days 13 to 16) stages of luteal 
phase than at earlier stages (Levy et al., 2001, 2003). The greater END content and mRNA 
expression coincided with high amounts of PGF2  present during luteolysis and concur with the 
fact that END1 secretion increases in response to PGF2  in vitro (Girsh et al., 1996a; Miyamoto 
et al., 1997) and in vivo in microdialysed CL (Ohtani et al., 1998).  However, END1 is not 
regulated by PGF2  early in the cycle and it is present in the natural CL (Wright et al., 2001; 
Choudhary et al., 2004). 
Peripheral plasma concentrations of END1 during the bovine estrous cycle remained low 
from days 2 to 12, increased on days 13 to 19 and reached the greatest values on days 20 to 22 
(Ohtani et al., 1998). Low expression of END1 peptide and mRNAs for END1, ECE1 and 
ENDRA (Ohtani et al., 1998; Mamluk et al., 2001; Levy et al., 2001; Wright et al., 2001; Levy 
et al., 2003; Choudhary et al., 2004) at early stages of the luteal phase are coincident with the 
time when the CL is refractory to luteolytic doses of PGF2  (Braun et al., 1988; Levy et al., 
2000). However, CL has enough PGF2  receptors from day 2 of estrous cycle for initiating 
luteolysis (Wiltbank et al., 1995). So, the lack of response of CL to the luteolytic action of 
PGF2  may be because incomplete neovascularization of CL in that developmental stage limits 
END1 synthesis (Levy et al., 2000). However, subsequent evidence indicated that endothelin 
system in the bovine CL is regulated by PGF2  in a dependent or independent manner 
according to the phase of the estrous cycle (Choudhary et al., 2004). Before day 10 of estrous 
cycle, the amounts of mRNA encoding END1, ECE1, ENDRA and ENDRB increased 
independently of PGF2 ; whereas PGF2  differentially affected expression of ppEND1 and 





support the involvement of END1 in the differential sensitivity of CL to PGF2  in early versus 
later stages of luteal phase. 
In recent years, data from various in vivo studies have confirmed and strengthened the 
concept that END1 is an important mediator of PGF2 -induced luteal regression. Infusions of 
BQ-610 (500 g), a highly specific ENDRA antagonist, every 12 h on d 16 through 18 of the 
estrous cycle in heifers delayed luteolysis for about 2 days (Keator et al., 2008). Chronic 
administration of BQ-610 into the CL through a minipump implanted in the ovary during the 
mid-luteal phase in sheep, decreased serum P4 concentration throughout first 12 h after a single 
injection of PGF2 . However, P4 progressively increased during the next 36 h, attaining a 
concentration similar to the control group 48 h after PGF2  (Doerr et al., 2008). Apparently, a 
direct action of PGF2  decreased serum P4 during early luteolysis, whereas END1 was 
required in later stages as indicated by the rise of P4 in BQ-610-treated ewes beginning 12 h 
after PGF2 ; this would imply that END1 may participate in structural rather than functional 
luteolysis. In contrast, administration of an ENDRB antagonist (BQ-788) in the same 
experiment did not reverse the reduction of P4 after PGF2  (Doerr et al., 2008). This finding 
agreed with the fact that ENDRB mRNA expression was almost absent in mid-phase CL (Doerr 
et al., 2008), indicating that END1 participates in the luteolytic cascade by activating ENDRA.  
Intraluteal injections of ENDRA antagonists (BQ-610, BQ-123 and LU-13522) were less 
effective to address the role of END1 PGF2 -induced luteolysis. A single injection of BQ-123 
(100 g) on days 8 to 9 of the estrous cycle in sheep diminished, but did not completely block 





Milvae, 2001). The authors suggested that activation of ENDRB may have contributed to the 
incomplete inhibition of END system or BQ-123 was less effective in blocking ENDRA than 
other antagonists. Also, single or multiple intraluteal injections of ENDRA antagonists during 
bovine mid-luteal phase were ineffective to prevent P4 decline as was reported in sheep. In both 
heifers (Keator et al., 2008) and cows (Watanabe et al., 2006) P4 concentration after a 
luteolytic dose of PGF2  decreased parallel to control females.  
To test the role of END1 in PGF2 -induced luteolysis, sheep were injected (im) with saline, 
7.5 mg of PGF2 , 100 g of END1, or 7.5 mg of PGF2  plus 100 g of END1 during mid-
luteal phase (Hinckley and Milvae, 2001). END1 transiently increased plasma P4 
concentrations that thereafter decreased progressively attaining minimal values simultaneously 
with saline-treated group. Dosage of PGF2  first decreased concentrations of P4 for about 6 h 
and then P4 increased to similar values as in saline-treated ewes. Interestingly, combination of 
PGF2  and END1 reduced plasma P4 concentration from 0.25 h to 48 h post-treatment, time at 
which P4 reached luteolytic concentrations (less than 0.5 ng/mL). The combination also 
shortened the estrous cycle (10.3 d) compared with the rest of the groups (about 16 d each). 
These findings support the role of END1 as a mediator of the intricate luteolytic cascade 
initiated by uterine PGF2  and modulated by luteal PGF2  and other local mediators. 
Apparently, presence of PGF2  is required so that END1 exerts its luteolytic effect as 







Role of END1 in steroid production by ovine granulosal cells collected from 
large preovulatory follicles 
Introduction 
In sheep, follicular growth occurs in a wave-like pattern with typically 3 to 4 follicular 
waves during every estrous cycle (Ginther et al., 1995; Bartlewski et al., 1999; Evans et al., 
2003). Follicular dominance is not as marked in sheep as is in the cow (Lopez-Sebastian et al., 
1997; Gonzalez-Bulnes et al., 2001; 2004). Neither the presence of a large follicle induced by 
exogenous FSH nor supraphysiological concentrations of estradiol released from implants 
prevented emergence of a new wave of follicles (Duggavathi et al., 2004; 2005; Barrett et al., 
2006). Likewise, more than 2 antral follicles from ultimate and penultimate waves of the cycle 
may reach ovulatory status and eventually ovulate (Souza et al., 1997; Bartlewski et al., 1999).   
Preovulatory follicles produce greater amounts of estradiol (Duggavathi et al., 2003); and 
elevated concentrations of circulating estradiol trigger the LH/FSH surge and the consequent 
ovulation process (Karsch et al., 1983). After the LH surge, the predominant pattern of steroid 
production by the preovulatory follicles changes rapidly from estrogen to progesterone as the 
main steroid secreted by granulosal and thecal cells (Murdoch and Dunn, 1982; Fortune and 
Hansel, 1985). The downregulation of P450-17 -hydroxylase and P450arom in thecal and 
granulosal cells, respectively, and upregulation of progesterone receptor in the two types of 
steroidogenic cells appear to support this change (Voss and Fortune, 1993a; Komar et al., 2001; 
Jo et al., 2002). Likewise, steroid production by granulosal and thecal cells of large follicles is 





2002), BMPs (Gliser et al., 2004; Campbell et al., 2006), BMP15 (Juengel et al., 2002), GDF9 
(Spicer et al., 2006; 2008), inhibin (Jimenez-Krassel et al., 2003), estradiol (Spicer et al., 2005), 
IGFs (Spicer et al., 2002; 2004), and END1 (Flores et al., 1992; Kamada et al., 1993; Acosta et 
al., 1998), modulate steroid production through autocrine and paracrine mechanisms, and might 
prevent premature differentiation of granulosal and thecal cells of  preovulatory follicles prior 
to LH/FSH surge.  
Endothelin 1, a 21-amino acid peptide, was described originally as a potent vasoconstrictor 
(Yanagisawa et al., 1988) and later associated with modulation of steroidogenesis in follicular 
and luteal tissue from rats (Tedeschi et al., 1992; 1994; Colagero et al., 1998), pigs (Iwai et al., 
1991; Flores et al., 1992; Kamada et al., 1992; 1993), cows (Girsh et al., 1996a; Miyamoto et 
al., 1997), ewes (Hinckley and Milvae, 2001; Doerr et al., 2008) and human beings (Denkova 
et al., 2000; Yaneva et al., 2003). Endothelin 1 is synthesized and secreted from ovarian 
granulosal cells, and greater amounts of END1 were detected in larger than in smaller antral 
follicles (Iwai et al., 1991; Flores et al., 2000). The antisteroidogenic effect on granulosal cells 
appeared to be mediated via ENDRA in pigs (Flores et al., 1995) and ENDRB in rats (Iwai et 
al., 1993). The END1 mRNA expression in pigs was detected first around the antral stage, 
increased as the follicles grew, and decreased rapidly after ovulation (Flores, 2000). In the rat 
ovary, inhibition of P4 production in granulosal cells by END1 was associated with 
downregulation of P450scc and 3 -HSD and upregulation of 20 -HSD, 5 -reductase and 3 -
HSD (Tedeschi et al., 1992), enzymes implicated in synthesis and metabolism of P4, 
respectively. Moreover, in bovine microdialyzed mature follicles, END1 inhibited P4 secretion 





of END1 in regulating steroidogenesis in sheep follicles, on the basis of previous experimental 
evidence, it is possible to speculate that END1 acting through autocrine and paracrine 
mechanisms, might prevent premature luteinization of granulosal cells prior to the LH surge in 
sheep as suggested in other species (Tedeschi et al., 1992; Flores, 2000).  
The objective of this study was to examine the effect of blocking ENDRA and ENDRB on 
follicular steroid production by granulosal cells from preovulatory follicles in sheep. The 
hypothesis was that END1 acting through ENDRA and/or ENDRB would inhibit steroid 
production, and therefore, prevent the premature luteinization of granulosal cells of ovine 
preovulatory follicles.  
Materials and methods 
General experimental procedure 
Seventeen nonpregnant cycling Suffolk ewes with at least one previous estrous cycle of 
normal length (15 to 19 days) were used in the experiment, conducted in fall of 2006 
(September-December) with ewes from the West Virginia University research flock. For 
observation of estrus (12 h intervals), ewes were penned with a vasectomized ram bearing a 
harness with a crayon in the area of the brisket; standing estrus was confirmed by teasing with 
another vasectomized ram. Fourteen days after estrus (estrus = day 0) ewes were injected (i.m.) 
with two doses (5 mg each) of PGF2  (Lutalyse®, Pfizer Animal Health, New York, NY) 3 h 
apart (Hawk, 1973) to induce luteolysis. To verify that a surge of LH had not occurred before 





and 36 in relation to the second dose of PGF2  (Fig. 6). Blood samples were refrigerated for 24 
h to allow them to clot, and then centrifuged for 20 minutes at 2500 rpm. Serum was collected 
and kept at -20° C until radioimmunoassayed for LH.  
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Figure 6. Protocol for collection of preovulatory follicles in sheep 
Thirty six to 40 hours after the second dose of PGF2 , ewes were anesthetized with 0.3 
mg/kg diazepam (Valium, 5 mg/ml; Roche Pharmaceutivals, Nutley, NJ) and 7 mg/kg ketamine 
(Vetamine, 100 mg/ml; Mallinckrodt Veterinary, Mundelein, IL), and then placed on a mixture 
of halothane (Halocarbon Laboratries, Riveredge, NJ), oxygen (2.0 L/min) and nitrous oxide 
gas (1.0 L/min) until bilateral ovariectomy was carried out through a mid-ventral incision. 
Immediately after ovariectomy, ovaries of each ewe were placed in cold phosphate buffered 





granulosal cells were harvested. All animal procedures were approved by WVU Institutional 
Animal Care and Use Committee (ACUC # 05-1205). 
Culture of granulosal cells and treatments 
Ovarian stroma was removed from 28 presumed preovulatory follicles (1.7 ± 0.8 
follicles/ewe) and the diameter of each dissected follicle was recorded (9.2 ± 1.5 mm). Using a 
22-gauge needle attached to 3 mL syringe, follicular fluid (FF) of each follicle was aspirated 
and centrifuged at 400 × g at 4 C for 5 min and the supernatant stored at -20 C for subsequent 
steroid determination by RIA; the remaining granulosal cells were added to those granulosal 
cells obtained directly from the follicle (see below).  
Each follicle was bisected under sterile conditions and granulosal cells were scraped gently 
from the basement membrane with a spatula into F12 Nutrient Mixture (Ham’s F12) media 
supplemented with sodium bicarbonate (0.01 M), antibiotics (1.5 mg of penicillin/mL and 2.5 
mg of streptomycin/mL) and 19-OH androstenedione (1 M) (Jimenez-Krassel and Ireland, 
2002). Granulosal cells were rinsed in cold Ham’s F12 supplemented medium, centrifuged at 
400 × g for 5 min at 4 C and resuspended in 200 L of cold Ham’s F12 supplemented medium. 
This last procedure was repeated twice. The number of cells and cell viability were estimated 
using a hemocytometer and trypan blue exclusion dye, respectively. According to the number 
of granulosal cells harvested from each follicle, additional volume of Ham’s F12 supplemented 
medium was added to cell suspension. Approximately 5.9 ± 2.6 × 10
5
 cells were cultured in 
each well. Nevertheless, because differentiating viable and non-viable cells by the trypan blue 





protein content per well and expressed as pg of steroid per g of protein per 24 h. Total protein 
at end point of the incubation period was quantified by colorimetric method using the 
Coomassie Protein Assay (Pierce Biotechnology, Inc., Rockford, IL). 
Aliquots of 15 L of granulosal cell suspension obtained from each presumed preovulatory 
follicle were cultured in 96-well plates containing a solution, previously equilibrated at 37 C, 
of 185 L of Ham’s F12 supplemented medium and treatments (described in Table 1). Cultures 
were incubated at 37 °C in a humidified atmosphere (5% CO2 and 95% air) for 24 h. Once 
finished the incubation period, the medium was removed carefully from each well, centrifuged 
(3000 × g for 1 min at room temperature) and stored at -20°C for subsequent steroid assays by 
RIA. Cultured granulosal cells and the remaining volume of granulosal cells in suspension were 
stored at -20°C.  
Radioimmunoassays for LH, progesterone, and estradiol 
Concentrations of P4 and E2 in FF and culture media, and LH concentrations in serum were 
measured in duplicate by RIA as previously described (Sheffel et al., 1982; Tortonese et al., 
1990; Goodman et al., 2004). LH assay sensitivity averaged 0.54 ng/ml, and the intraassay 
coefficient of variation was 15%. Intraassays coefficient of variation and sensitivities for P4 and 
E2 in unextracted FF were 8.6%, and 34 pg/tube for P4 and 10.6%, and 32 pg/tube for E2, 
respectively. For P4 and E2 in culture media, the inter- and intra-assay coefficient of variation 






Table 1. Treatments used to evaluate the role of END1 in steroid production by granulosal 
cells from preovulatory follicles in sheep. 
 
Treatments Description  Doses 
1 Control Ham’s F12 (Sigma-Aldrich, Milwaukee, WI) supplemented 
media 
─ 
2 LH Luteinizing hormone (LH, NIADDK-oLH-25 AFP 5551B;) 150 ng/mL 
3 END1 Endothelin-1 peptide (END1; Bachem Bioscience Inc, King 
of Prussia, PA) 
100 nM 
4 LH+ END1  ─ 
5 ENDRAa selective END receptor type A antagonist (ENDRA): BQ-
610 (Azepane-1-carbonyl-leu-D-Trp(For)-D-Trp-OH; 
Bachem Bioscience Inc, King of Prussia, PA) 
1500 nM 
6 ENDRAa+LH+ END1  ─ 
7 ENDRBa selective END receptor type B antagonist (ENDRB): BQ-
788 (N-cis-2,6-Dimethylpiperidinocarbonyl)-D-Nle-OH; 
Bachem Bioscience Inc, King of Prussia, PA)  
1000 nM 
8 ENDRBa +LH+END1  ─ 






Concentrations of P4 and E2 in culture media were evaluated by one-way analysis of 
variance using the General Linear Model (GLM) procedure of SAS (SAS Institute; Cary, NC). 
Differences among means were compared by the LSM procedure of SAS. Data were expressed 
as mean ± SEM. Antral follicles with greater concentrations of P4 and androgens than E2 were 
considered atretic (Morr et al., 1978; Ireland and Roche, 1982), and estrogen-inactive (P4>E2) 
(Ireland and Roche, 1983) follicles were removed from the analysis. Estrogen-active follicles 





ng/ml; 2: > 250  350 ng/ml, and 3: > 350 ng/ml) and included as a discrete variable in the 
statistical model. Two ewes had concentrations of LH greater than 180 ng/ml in samples 
collected at 24 or 30 h after the second dose of PGF2 , and their follicles were excluded from 
the analysis. The final number of follicles examined was 20, which were collected from 13 
ewes.  For 9 of these follicles, cells were cultured in duplicate and the average value was 
utilized.  
Results 
Accumulation of E2 and P4 was not affected by either LH or END1 or the END receptor 
blockers (Fig 7). Correlations between concentration of E2 in FF and E2 and P4 accumulation in 
the culture media were 0.30 (P < 0.0001) and 0.26 (P < 0.0004), respectively. Granulosal cells 
from follicles with the greatest concentration of E2 in FF produced on the average significantly 
more E2 and P4 than follicles with lower concentrations of E2 in FF (Table 2). Treatments did 
not affect accumulation of E2 and P4 in any of the categories of follicles considered (Fig 8). 
However, for all treatments, granulosal cells from preovulatory follicles with the greatest 
concentration of E2 in FF produced greater amounts of E2 and P4 than preovulatory follicles 









Table 2. Steroid accumulation in media from cultured granulosal cells according to 









≤ 250 > 250 ≤ 350 > 350 
Estradiol        0.75 ± 0.06 
a
       0.80 ± 0.08 
a
       1.97 ± 0.07 
b        a,b P<0.0001 
Progesterone 145.0 ± 3.9 
a
 170.8 ± 5.9 
b

































Figure 7. Effects of LH, END1, ENDRAa (BQ-610) and ENDRBa (BQ-788) on production of 
estradiol and progesterone by ovine granulosal cells isolated from preovulatory follicles. Bars 
represent mean ± SEM of estradiol (panel A) or progesterone (panel B) accumulation expressed 











































































LH (150 ng/ml) − + − + − + − + − +
END1 (100 nM) − − + + − + − + − +
ENDRAa (1500 nM) − − − − + + − − + +









Figure 8. Effects of LH, END1, ENDRAa (BQ-610) and ENDRBa (BQ-788) on production of 
estradiol and progesterone by ovine granulosal cells isolated from preovulatory follicles. 
According to concentration of estradiol in follicular fluid, preovulatory follicles were 
categorized into three groups (1:  250 ng/ml; 2: > 250  350 ng/ml, and 3:  350 ng/ml).  Bars 
represent mean ± SEM of estradiol (panel A) and progesterone (panel B) accumulation 
expressed in pg/ g of protein in 24 h. Values were statistically different between groups 1 and 












































LH (150 ng/ml) − + − + − + − + − +
END1 (100 nM) − − + + − + − + − +
ENDRAa (1500 nM) − − − − + + − − + +
ENDRBa (1000 nM) − − − − − − + + + +












































Granulosal cells from preovulatory follicles with greater concentrations of estradiol 
produced more E2 and P4, most likely due to the greater steroidogenic capacity of these follicles 
(Tian et al., 1995) compared to follicles with lower estrogenic production. Dominant follicles 
expressed greater amounts of mRNA for LH receptor, P450scc, P450c17 and 3 HSD in thecal 
cells and P450arom in granulosal cells than subordinate follicles (Xu et al., 1995b; Bao et al., 
1997a; Bao et al., 1997b). Moreover, follicular dominance was associated with onset of 
expression of LH receptor and 3 HSD in granulosal cells (Bao et al., 1997a; Bao et al., 1997b; 
Beg et al., 2001). Hence, in the preovulatory follicles collected in this study, greater steroid 
production may be supported by a greater expression of LH receptor and steroidogenic 
enzymes in the two populations of endocrine cells,  theca and granulosa. It is clear that some 
preovulatory follicles collected from either the same or different animals may have had 
functional advantages over others with lower rank. Thus, granulosal cells from those follicles 
reflected more steroidogenic capacity with greater accumulation of E2 and P4 after 24 h of 
culture. In addition, given that the substrate for synthesis of estradiol was provided in culture 
media, aromatization of androstenedione to estradiol by granulosal cells was carried out 
rapidly.  
Unexpectedly, LH did not induce an increase of either E2 or P4. Evidence indicated that LH 
and FSH stimulated steroid production by granulosal cells in vitro and END1 prevented that 
increment in other species (Iwai et al., 1991; Tedeschi et al., 1992; Kamada et al., 1993; Flores 
et al., 1999). However, responsiveness of LH receptors in follicles exposed to sustained 





1981), most likely because components of the downstream signaling pathway were disrupted 
(Ekstrom and Hunzicker-Dunn, 1989; Gudermann et al., 1995). Aggregation of receptors and 
receptor internalization are other mechanisms of agonist-induced desensitization of LH 
receptors (Amsterdam et al., 1980; Ghinea et al., 1992; Gudermann et al., 1995). In this study 
preovulatory follicles were collected at a specific follicular stage prior to LH surge, but were 
exposed to increasing concentrations of LH over time (Karsch et al., 1983; Fortune and Hansel, 
1985). In that circumstance, presence of elevated and sustained concentrations of LH in culture 
media may have induced deactivation of LH receptors in granulosal cells, and prevented 
stimulation of E2 and P4 production. 
It was hypothesized that END1, via either ENDRA or ENDRB, would regulate follicular 
steroid production and prevent premature luteinization of granulosal cells before the LH surge 
in sheep, as suggested for other species (Tedeschi et al., 1992; Flores, 2000). In this 
experiment, neither individual nor combined presence of LH and END1 in the culture medium 
affected the patterns of E2 and P4 secretion by granulosal cells isolated from preovulatory 
follicles. Hence, the hypothesis that END1 may modulate steroid production by granulosal cells 
from preovulatory follicles was not supported. Although antisteroidogenic actions of END1 
were demonstrated in follicles of rats (Tedeschi et al., 1992; 1994), pigs (Iwai et al., 1991; 
Flores et al., 1992; Kamada et al., 1993) and human beings (Denkova et al., 2000; Yaneva et 
al., 2003), such a role of END1 has not been reported in sheep. Attempts to identify END1 by 
immunohistochemistry in follicles from days 2 to 6 of the estrous cycle in sheep were not 
productive (Perea et al., unpublished data). However, in microdialyzed large bovine follicles, 





1999). Moreover, LH increased END1 release from mature follicles (Acosta et al., 1998), and 
the presence of ENDRA and ENDRB was detected in the theca of bovine follicles (Acosta et 
al., 1999). Because the presence of END1 in preovulatory follicles was associated with other 
vasoactive peptides such as angiotensin II and atrial natriuretic peptide in microdialyzed mature 
follicles (Acosta et al., 1999), a role of END1 in modulating blood flow into the follicle may be 
one of its functions.  
In conclusion, these results did not demonstrate effects of END1 on LH-stimulated steroid 
production by granulosal cells from preovulatory follicles. Future research is needed to clarify 
whether END1 has a role of in follicular function in the sheep. Given that earlier in vitro 
studies in pigs, FSH-simulated P4 production by granulosal cells collected from small- and 
medium-sized follicles was inhibited by END1 (Kamada et al., 1993; Flores et al., 1992; 1999), 
such future research should include preovulatory follicles collected earlier of and incorporation 











Effects of blocking endothelin receptor type A during spontaneous and 
PGF2 -induced luteolysis on morphological and functional characteristics of 
the corpus luteum and length of the estrous cycle in the sheep 
Introduction 
After ovulation, the collapsed ovulatory follicle undergoes dramatic cellular and structural 
changes that result in formation of the corpus luteum. The corpus luteum is a transient 
endocrine gland that produces increasing amounts of P4 until the mid-luteal phase, at which 
time P4 reaches steady state concentrations. Progesterone plays important roles modulating the 
hypothalamic–hypophyseal axis and promoting appropriate uterine physiological conditions to 
sustain development of the embryo/fetus during pregnancy. In the absence of an embryo in the 
uterus, CL demise in function and a new estrous cycle is initiated a few days later. 
Luteal regression involves two consecutive and complementary processes through which the 
CL loses steroidogenic capacity without apparent changes in the structure of the tissue 
(functional luteolysis), followed by degradation of all cellular and structural components of the 
CL, with the concomitant reduction of luteal weight and size (structural luteolysis). Functional 
luteolysis was associated with decline of circulating concentrations of P4 and a transient 
increase followed by progressive reduction in blood flow to the CL (McCracken et al., 1970; 
Niswender et al., 1975; 1976; Nett et al., 1976; Acosta et al., 2003). Once P4 decreases, 
structural changes imply degradation of the cellular matrix and apoptosis of all cellular 
components of the CL (Hoyer, 1998; Pate and Keyes, 2001; Smith et al., 2002; Stocco et al., 





the luteal phase, or after an injection of exogenous PGF2  during mid-luteal phase of the 
estrous cycle (Zarco et al., 1988a; Niswender et al., 2000; Tsai et al., 2001). Luteolysis initiated 
by uterine PGF2  is mediated by numerous local (intraluteal) factors such as NO (Jaroszewski 
et al., 2003), angiotensin II (Shirasuna et al., 2004), TNF- , INF- , IL-1  (Neuvians et al., 
2004), and END1 (Girsh et al., 1996a; Hinckley and Milvae, 2001) secreted by different luteal 
cells.  
Substantial evidence demonstrated that END1 is a relevant mediator of luteolytic actions of 
PGF2  (Girsh et al., 1996a; 1996b; Miyamoto et al., 1997; Ohtani et al., 1998; Hinckley and 
Milvae, 2001; Keator et al., 2008).  Endothelin 1, a 21-amino acid peptide, originally isolated 
from porcine aortic endothelial cells as a potent vasoconstrictor (Yanagisawa et al., 1988), is 
involved in a wide variety of physiologic and pathologic roles in numerous mammalian tissues 
(Nussdorfer et al., 1999; Kedezierski and Yanagisawa, 2001). Two G protein-coupled receptors 
have been described for END1 (Nussdorfer et al., 1999). Type A (ENDRA) mediated luteolytic 
actions of PGF2  (Girsh et al., 1996b; Doerr et al., 2008; Keator et al., 2008). In the ruminant 
CL, END1 reduced both basal and LH-stimulated P4 secretion in a dose-dependent manner 
(Girsh et al., 1996a; Hinckley and Milvae, 2001), and the inhibitory effect was prevented by the 
addition of a selective ENDRA receptor antagonist (Girsh et al., 1996a).  
In recent years, data from various in vivo studies have confirmed and strengthened the 
concept that END1 is an important mediator of PGF2 -induced luteal regression. Although 
intraluteal injection of BQ-123 (an ENDRA antagonist) did not reverse completely the 





effectively reduced P4 concentrations by 48 h post-treatment, and shortened the length of the 
cycle (Hinckley and Milvae, 2001). However, separate administration of either END1 or PGF2  
at the same dosage, did not induce luteolysis in sheep (Hinckley and Milvae, 2001). 
Intrauterine infusions of BQ-610, a highly specific ENDRA antagonist, every 12 h on d 16 
through 18 of the estrous cycle in heifers delayed luteolysis for about 2 days (Keator et al., 
2008). Chronic administration of BQ-610 into the sheep CL through a minipump implanted in 
the ovary during the mid-luteal phase allowed decreased serum P4 concentration throughout the 
first 12 h after a single injection of PGF2 . However, P4 progressively increased during the next 
36 h, attaining a concentration similar to the control group by 48 h after PGF2  (Doerr et al., 
2008). Apparently, a direct action of PGF2  decreased serum P4 during early luteolysis, 
whereas END1 was required in later stages as indicated by the rise of P4 in BQ-610-treated 
ewes beginning 12 h after PGF2 . In addition, blockade of ENDRA during PGF2 -induced 
luteolysis in cows, prevented the increase of caspase 3 mRNA by 24 h compared with controls 
(Watanabe et al., 2006).  These findings indicate that END1 may participate in structural rather 
than functional luteolysis, stimulating expression of pro-apoptotic factors. 
Two experiments were carried out to study the effects of END1 on functional and structural 
changes of the CL during either spontaneous or PGF2 -induced luteolysis in the sheep. In the 
first experiment, the ENDRA antagonist BQ-610 was delivered into the CL through an osmotic 
minipump to examine the expression of genes related with P4 production and structural 
luteolysis at 6 and 24 h after exogenous PGF2 . It was hypothesized that sustained blockade of 





In the second experiment, the same approach was used to examine the effects of the 
sustained blockade of ENDRA during spontaneous luteolysis on the length of the estrous cycle 
and functional and structural characteristics of the CL. It was hypothesized that chronic 
delivery of BQ-610 into the CL would prevent or delay the luteal regression induced by 
endogenous PGF2 , increasing the length of estrous cycle. 
Experiment 2: Effect of blocking endothelin receptor type A on gene 
expression during PGF2 -induced luteolysis in sheep 
Materials and methods 
General experimental procedure 
Forty five nonpregnant mixed-breed ewes with at least one previous estrous cycle of normal 
length (15 to 19 days) were used in the experiment, conducted in fall of 2007 and 2008 
(September-December) with ewes from the West Virginia University research flock. For 
observation of estrus (12 h intervals), ewes were penned with a vasectomized ram bearing a 
harness with a crayon in the area of the brisket; standing estrus was confirmed by teasing with 
another vasectomized ram. Treatment was begun at day 7.5 to 9 of the estrous cycle (standing 
estrus = day 0). Ewes were assigned randomly to receive one of the following treatments: 
Alzet® mini-osmotic pump (model 2002; Durect Corporation, Cupertino, CA) loaded with 
either vehicle (200 L of 2:1 methanol/saline solution) or 2.5 mg of END receptor A 
antagonist, BQ-610 (Azepane-1-carbonyl-leu-D-Trp(For)-D-Trp-OH), diluted in  200 L of 





mini-osmotic pumps (Bachem Bioscience Inc, King of Prussia, PA), designed to deliver 0.52 ± 
0.02 L/h for approximately 14 days, were kept overnight in sterile 0.9% saline solution at 
37 C until implantation in the ovarian pedicle. Thus, the expected delivered dosage was 6.25 
g/h of BQ-610. 
Ewes were initially anesthetized with 0.3 mg/kg diazepam (Valium, i.v., 5 mg/ml; Roche 
Pharmaceuticals, Nutley, NJ) and 7 mg/kg ketavet (Ketamine HCL, i.v.,) and then placed on a 
mixture of halothane, oxygen (2.0 L/min), and nitrous oxide gas (1.0 L/min) until mid-ventral 
laparotomy was finished. Ovaries were examined carefully, and in the presence of multiple CL, 
one was selected for implantation of the catheter connected to the mini pump. Additional CL in 
the same ovary were enucleated and an absorbable gelatin sponge was placed inside the 
remaining cavity (Gelfoam®, Pfizer Inc, New York, NY) as a hemostatic component. The 
contralateral ovary was removed if it contained additional CL. Each minipump was positioned 
in the mesoovarium and the attached catheter stabilized within the CL following the surgical 
procedure previously described (Doerr et al., 2008). All ewes received a dose (i.m.) 3 × 10
6
 IU 
of penicillin G immediately after surgery.  
A luteolytic dose of PGF2  (25 mg; Lutalyse®, Pfizer Animal Health, New York, NY) was 
injected (i.m.) 48 h after surgery, and 6 or 24 h later ewes were euthanized, the correct position 
of the pumps and catheters was verified, and ovaries were collected. Ewes in the control group 
(no minipump implantation) received a saline injection (5 ml; i.m.) on day 9, 10 or 11 of the 
estrous cycle, and 6 or 24 h later ovaries were removed by mid-ventral laparatomy as described 
above. Jugular blood samples (8 ml) were collected at 3 h intervals from hour 0 to 6 (6-h 





concentrations. Blood samples were refrigerated for 24 hours to allow them to clot, and then 
centrifuged for 20 minutes at 2500 rpm. Serum was collected and stored at -20° C until 
radioimmunoassay for P4. All animal procedures were approved by WVU Institutional Animal 
Care and Use Committee (ACUC # 05-1205). 
Once removed, ovaries were refrigerated in ice-cold PBS, transported to the laboratory, and 
each CL was dissected, weighed, and sectioned into pieces that were weighed individually, then 
frozen in liquid nitrogen and stored at -80°C. One piece of each CL was homogenized in PBS 
(1 ml/100 mg of tissue), centrifuged, and supernatant stored at -20 °C until assayed for P4. 
Number of ewes per treatment and times of tissue collection are shown in Table 3. 
Table 3. Numbers of ewes per treatment and time of tissue collection 
 
Time of tissue 
collection 
Treatment 
BQ-610 Vehicle Control 
6-h 9 6 6 
24-h 10 7 7 
Total 19 13 13 
 
Real-Time RT-PCR 
The relative expression of a group of genes associated with luteal function or involved in 
functional and structural luteolysis, as reported elsewhere (Juengel et al., 2000; Tsai et al., 
2001; Diaz et al., 2002; Smith et al., 2002; Taniguchi et al., 2002; Kliem et al., 2007; 2009), 
was quantified by real-time PCR. Total RNA was isolated from frozen luteal tissue using Tri-





solubilized in RNAse-free water, the quality and quantity of each RNA sample were assessed 
by 1% agarose gel electrophoresis and by spectrophotometry (Nano Drop Technologies, 
Wilmington, DE), respectively. Purified RNA samples were treated with DNAse (Invitrogen, 
Carlsbad, CA) to remove residual DNA contamination. To assure that low expression of a gene 
was not negatively affecting the Ct values and confirming variability within replicates, the RT-
PCR was tested at total RNA concentrations of 0.5, 1.0 and 2.0 g/ L. The gene expression 
data reported in this study were from the 2.0 g of total mRNA concentration.  
To generate first-strand cDNA, total RNA was reverse transcribed in a reaction volume of 
20 L containing sample RNA (2.0 g), dNTP mix (10 nM), oligo dT primer (450 ng) and 
Superscript II reverse transcriptase (200 U) (Invitrogen, Carlsbad, CA). Real-time PCR was 
carried out using the approach reported by Pfaffl (2001) and following the procedure described 
by Goravanahally et al. (2009). Briefly, representative RNA samples from each treatment were 
pooled and used to produce first-strand cDNA as described above. Five consecutive dilutions 
(1:10) of cDNA were used to generate a standard curve to estimate the efficiency of the specific 
primers for each gene. The optimum efficiency of the PCR reactions was standardized between 
90 to 110%. Melting curve from optimization reactions of each set of primers assured the 
absence of secondary products.  
Oligonucleotide primers were designed with primer3 software (Rozen and Skaletsky, 2000) 
based on the mRNA sequences of Ovis aries. In the event of mRNA sequences not previously 
described in sheep, Bos taurus mRNA sequences were used. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was the reference gene to normalize the expression values of the 





characteristics of each gene primer included in the study. Quantitative PCR reactions were 
carried out in duplicate for each cDNA sample in an iCycler iQ Real-Time PCR Detection 
System (Bio-Rad, Hercules, CA), using a total reaction volume of 25 L that included SYBR 
Green Supermix (Bio-Rad, Hercules, CA), 1 M of each primer and non-diluted target cDNA 
(2 L). Real-time PCR conditions were: 30 sec at 95 C followed for 40 cycles at 95 C for 30 
sec to denature, 30 sec at 60 C to anneal, and 1 min at 72 C for extension.  
Radioimmunoassays for progesterone 
Concentrations of P4 in serum and luteal tissue were measured in duplicate by RIA as 
previously described (Sheffel et al., 1982). Assay sensitivity averaged 0.15 ng/ml, and inter- 
and intraassay coefficients of variation were 13.8% and 13.0%, respectively. 
Statistical Analysis 
The effect of treatments on concentrations of serum and luteal P4 and luteal weight for each 
time of tissue collection (6-h and 24-h groups) was evaluated by one-way analysis of variance 
using the General Linear Model (GLM) procedure of SAS (SAS Institute; Cary, NC). 
Differences among means were compared by the LSM procedure of SAS. To examine 
differences in gene expression according to treatment, time, and treatment × time, a complete 
block design was applied and analyzed by the GLM procedure of SAS. Differences among 
means were compared by orthogonal contrasts. Contrasts tested were (a) PGF2  versus control 





























StAR NM_001009243 O. aries F: 5’-TGCTGAGTAAAGTGATCCCTGA-3’ 
R: 5’-AGGACCTTGATCTCCTTGACAC-3’ 
148 60 -3.631 
3 HSD NM_174343 B. taurus F: 5’-CCACACCAAAGCTACGATGA-3’ 
R: 3’-TGTAAATTGGACTGAGCAGGAA-3’ 
148 60 -3.419 
20 HSD XM_868164 B. taurus F: 5’-CTGAACGCATTGCTGAGAAC-3’ 
R: 3’-AACTCCTCGTGAAAGGGGTAA-3’ 
148 60 -3.601 
VEGF NM_001025110 O. aries F: 5’-TTGCTGCTCTACCTTCACCAT-3’ 
R: 5’-TCTGGGTACTCCTGGAAGATGT-3’ 
158 60 -3.370 
eNOS DQ015701 O. aries F: 5’-TGTTGGATTCCCTGTACTATCTCA-3’ 
R: 5’-AACTTCTGGTCCAGTCTCTTATGG-3’ 
240 60 -3.262 
TIMP-1 NM_001009319 O. aries F: 5’-CCAGACATCCGATTCATCTACA-3’ 
R: 3’-GCAGAACTCATGCTGTTCCA-3’ 
167 60 -3.558 
TIMP-2 NM_174472 B. taurus F: 5’-AGTTCTTCGCCTGCATCAA-3’ 
R: 3’-AGCTGGACCAGTCTGAACTCTT-3’ 
159 60 -3.376 
Bcl-2 DQ152929 O. aries F: 5’-TGGATGACCGAGTACCTGAA-3’ 
R: 3’-CAGCCAGGAGAAATCAAACAG-3’ 
120 60 -3.314 
Bax AF163774 O. aries F: 5’-GAAGCGCATTGGAGATGAA-3’ 
R: 3’-AAGTAGAAAAGGGCGACAACC-3’ 
159 60 -3.286 
MMP-2 AF267159 O. aries F: 5’-TTCATCTGGCGAACAGTGAC-3’ 
R: 3’-CAGTATTCGTTCCCTGCAAAG-3’ 
149 60 -3.264 
MMP-14 AF267160 O. aries F: 5’-TGAGAGGAAGGATGGCAAGT-3’ 
R: 3’-TCCAGAAGAGAGCAGCATCA-3’ 
149 60 -3.376 
Fas-R NM_001123003 O. aries F: 5’-CGGAAGAATGGTATGGAGGA-3’ 
R: 3’-TGCAAGAGCTTTTGGGAGAT-3’ 
162 60 -3.375 
Caspase 3 AF068837 O. aries F: 5’-GGATTATCCTGAAATGGGTTTATG-3’ 
R: 3’-GATCGTTTTTAATCCTGACTTCGT-3’ 
155 60 -3.266 
Caspase 8 NM_001045970 B. taurus F: 5’-TGTCACAATCGCTTCCAGAG-3’ 
R: 3’-AGTATCCCCGAGGTTTGCTT-3’ 
126 60 -3.311 
GAPDH AF030943 O. aries F: 5’-TCTCAAGGGCATTCTAGGCTAC-3’ 
R: 3’-TGTAGCCGAATTCATTGTCG-3’ 









Corpus luteum weight  
The weights of the CL collected 6 h after injection of saline or PGF2  were not affected by 
treatments. Apparently, treatment with BQ-610 did not prevent the luteolytic effect of 
exogenous PGF2 , because CL from BQ-610-treated ewes were lighter (P < 0.02) than those 
from control ewes 24-h after PGF2  or saline (Fig 9). 
Serum and luteal progesterone  
Given that control ewes had one or more CL in the ovaries, while treated ewes had only one 
CL, concentrations of P4 for each collection time were compared as the change from hour 0 
(time of PGF2  or saline injection). In ewes from which CL were removed at 6 h, change in 
concentration of P4 3 h after PGF2  was less negative  in control than in BQ-610- and vehicle-
treated ewes (P < 0.01). By 6 h, the P4 decrease was similar in all treatments (Fig 10). In 
contrast, P4 concentrations in BQ-610-treated and vehicle-treated ewes from which CL were 
removed at 24 h, declined progressively by greater than 0.5 ng/ml by 24 h after PGF2 , while in 
control ewes P4 remained more than 0.5 ng/ml above the initial value throughout the sampling 
period (Fig. 11). Six hours after onset of induced luteolysis, content of luteal P4 in BQ-610-
treated and vehicle-treated ewes that received PGF2  had decreased by ~ 65% and ~ 61%, 
respectively, with respect to luteal content of P4 in control ewes. By 24 h after PGF2  injection, 
luteal content of P4 in BQ-610-treated and vehicle-treated ewes was around 1/9 and 1/3, 





one ewe had a secretion pattern of serum P4 similar to that reported by Doerr et al. (2008) in 
sheep treated with BQ-610. In this responsive BQ-610-treated ewe, P4 concentration declined 
progressively from 2.5 ng/ml at time 0 to 0.9 ng/ml 9 h after PGF2  injection, remained below 1 
ng/ml until h 15 and then increased to 1.5 ng/ml by h 24 after PGF2 . Concentration of luteal P4 
in this animal was 12.8 g/g and the luteal pattern of gene expression was similar to mid-cycle 
CL from the control ewes. 
Gene expression 
Expression of StAR and 3 -HSD mRNA were affected by treatment (P = 0.05 and P < 
0.0001, respectively), and the expression of each gene was lower in PGF2 -treated than in 
control ewes (P < 0.03; P < 0.0001, respectively); but did not differ between BQ-610- and 
vehicle-treated CL at any time (Fig 13). For 20 -HSD mRNA, there was an effect of treatment 
(P < 0.0001), time (P < 0.01) and treatment × time (P < 0.0001), reflected in the upregulation of 
this gene in PGF2 -treated compared with control animals (P < 0.02) and in BQ-610-treated 
ewes compared with vehicle-treated animals (P < 0.02; Fig 13). Expression of VEGF mRNA 
was affected by treatment (P < 0.0001), time (P < 0.01) and treatment × time (P < 0.04), 
specifically being lower in PGF2 -treated than in control ewes (P < 0.0001; Fig 14). Treatment 
(P < 0.0001) and treatment × time (P < 0.0001) affected mRNA expression of TIMP-1 (Fig 14), 
which was lower in PGF2 -treated than in control ewes (P < 0.0001). In contrast, TIMP-2 
mRNA at 6 and 24 h averaged 1.35 ± 0.28 and 1.03 ± 0.27, respectively, and did not differ with 





Expression of MMP-1 mRNA was affected by time, while the contrast BQ-610 versus 
PGF2  only tended to be different (0.90 ± 0.20 versus 0.57 ± 0.20, respectively; P<0.10). For 
MMP-14, treatment (P = 0.0002), time (P < 0.0001) and treatment × time (P = 0.0005) differed, 
and its expression was lower in PGF2 -treated versus control ewes (P < 0.0001; Fig 15); and as 
judged by least squares means, this transcript was greater in vehicle-treated than in BQ-610-
treated ewes followed by control animals at 24 h (P < 0.01). Time and treatment affected 
expression of eNOS (Fig 15), which was lower in PGF2 -treated than in control ewes (1.03 ± 
0.14 and 1.47 ± 0.13, respectively; P = 0.001).  
In regard to the genes involved in structural luteolysis, Bcl-2 expression was affected by 
treatment (P = 0.06) and time (P < 0.002; Fig 16), whereas its expression in PGF2 -treated ewes 
was greater than in control ewes (1.22 ± 0.30 versus 0.63 ± 0.28, respectively; P < 0.03). Time 
(P < 0.0001) and treatment × time (P < 0.005) affected Bax mRNA expression (Fig 16), with a 
trend for a greater expression in BQ-610-treated than in vehicle-treated CL (0.86 ± 0.1 versus 
0.68 ± 0.1; P < 0.09). The Bcl-2/Bax ratio at 6 h was greater in BQ-610-treated than in control 
ewes (P < 0.01) (2.29 ± 0.38 versus 0.84 ± 0.38, respectively). In contrast, at 24 h, Bcl-2/Bax 
ratio tended to be lower in BQ-610-treated ewes than in control ewes (P < 0.09) (0.79 ± 0.38 
versus 1.70 ± 0.33, respectively). For Fas-R transcript, time (P < 0.0001) and treatment × time 
(P = 0.001) differed, and treatment (P = 0.09) and PGF2  versus control tended to differ (P < 
0.09; Fig 16). For caspases 3 and 8, mRNA expression was affected by treatment, time and 
treatment × time (all P ≤ 0.01), and both contrasts, PGF2  versus control and BQ-610 versus 





treated ewes for both caspases 3 and 8 was upregulated at 24 h compared to either vehicle-

































Figure 9. Effect of chronic administration of either BQ-610 or vehicle during PGF2 -induced luteolysis 
on corpus luteum weight in sheep. Corpora lutea were collected 6 h or 24 h after PGF2  injection in BQ-
610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of 
corpus luteum weight (g). Values differed among treatments (
a,b
P < 0.07; 
a,c






















Figure 10. Effect of chronic administration of either BQ-610 or vehicle during PGF2 -induced luteolysis 
on changes in serum concentrations of progesterone in ewes from which CL were removed at 6 h. 
Jugular blood samples were collected at 3-h intervals from hour 0 to 6 after PGF2  injection (time 0) in 
BQ-610- (○) and vehicle-treated (■) ewes or after saline injection in control ewes (▲). Data points 
represent differences in progesterone (ng/ml) from hour 0 (mean ± SEM). Values in control and PGF2 -
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Figure 11. Effect of chronic administration of either BQ-610 or vehicle during PGF2 -induced luteolysis 
on changes in serum concentration of progesterone in ewes from which CL were removed at 24 h. 
Jugular blood samples were collected at 3-h intervals from hour 0 to 24 (24-h group) after PGF2  
injection (time 0) in BQ-610- (○) and vehicle-treated (■) ewes or after saline injection in control ewes 
(▲). Data points represent differences in progesterone (ng/ml) from hour 0 (mean ± SEM). Values in 




















Figure 12. Effect of chronic administration of either BQ-610 or vehicle during PGF2 -induced luteolysis 
on luteal content of progesterone in sheep. Corpora lutea were collected 6 h or 24 h after PGF2  
injection in BQ-610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent 





P < 0.0005). 
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Figure 13. Effects of chronic administration of either BQ-610 or vehicle during PGF2 -induced 
luteolysis on gene expression. Corpora lutea were collected 6 h and 24 h after PGF2  injection in BQ-
610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of 
normalized mRNA expression for StAR (panel A), which was affected by treatment (P = 0.05) and the 
contrast PGF2  versus control (
a,b
P < 0.03); 3 HSD (panel B), which varied with treatment (P < 0.0001), 
and the contrast PGF2 versus control (
a,b
P < 0.0001); and 20 HSD (panel C), which varied with time (P 
< 0.0001), treatment (P < 0.01), time × treatment (P < 0.0001), the contrasts PGF2  versus control and 
and BQ-10 versus vehicle (P < 0.02); least squares means for treatments at 24 h differed (
a,b
P = 0.004; 
a,c
P < 0.0001; 
b,c
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Figure 14. Effects of chronic administration of either BQ-610 or vehicle during PGF2 -induced 
luteolysis on gene expression. Corpora lutea were collected 6 h and 24 h after PGF2  injection in BQ-
610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of 
normalized mRNA expression for VEGF (panel A), which varied with time (P < 0.01), treatment (P < 
0.0001), time × treatment (P < 0.04), and the contrast PGF2  versus control (
a,b
P < 0.0001), least squares 
means for treatments differed (
a,b
P < 0.0001; 
a,c
P < 0.003; 
b,c
P < 0.0001); and TIMP-1 (panel B), which 
was affected by treatment (P < 0.0001), time × treatment (P < 0.0001), and the contrast PGF2  versus 
control (
a,b
P < 0.0001), least squares means for treatments differed (
a,b
P < 0.0001; 
b,c
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Figure 15. Effects of chronic administration of either BQ-610 or vehicle during PGF2 -induced 
luteolysis on gene expression. Corpora lutea were collected 6 h and 24 h after PGF2  injection in BQ-
610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of 
normalized mRNA expression for MMP-14 (panel A), which was affected by time (P < 0.0001), 
treatment (P = 0.0002), time × treatment (P = 0.0005), and the contrast PGF2  versus control (P < 
0.0001), least squares means for treatments at 24 h differed (
a,b
P < 0.01; 
a,c
P < 0.0001); and eNOS (panel 
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Figure 16. Effects of chronic administration of either BQ-610 or vehicle during PGF2 -induced 
luteolysis on gene expression. Corpora lutea were collected 6 h and 24 h after PGF2  injection in BQ-
610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of 
normalized mRNA expression for Bcl-2 (panel A), which was affected by time (P = 0.002), and 
treatment (P = 0.06); Bax (panel B), time (P < 0.0001), which was affected by time × treatment (P = 
0.003), and the contrast BQ-610 versus vehicle (P < 0.09), least squares means for treatments differed 
(
a,e
P < 0.0001; 
b,c
P < 0.04; 
b,e
P < 0.002; 
c,b
P < 0.04; 
c,d
P < 0.0001); and Fas-R (panel C), which varied 
with time (P < 0.0001), and  time × treatment (P = 0.001), least squares means for treatments differed 
(
a,c
P ≤ 0.0002; 
a,d
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Figure 17. Effect of chronic administration of either BQ-610 or vehicle during PGF2 -induced luteolysis 
on gene expression. Corpora lutea were collected 6 h and 24 h after PGF2  injection in BQ-610- and 
vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of normalized 
mRNA expression for caspase 3 (panel A), time (P = 0.001), which varied with treatment (P < 0.0001), 
time × treatment (P = 0.01), the contrasts PGF2  versus control (P < 0.0005) and BQ-10 versus vehicle 







and caspase 8 (panel B), which was affected by time (P < 0.01), treatment (P = 0.0001), time × 
treatment (P = 0.0005), the contrasts PGF2  versus control (P < 0.02) and BQ-10 versus vehicle (P = 
0.0001), least squares means for treatments at 24 h differed (
a,b
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Data from serum and luteal concentrations of P4 (Fig. 10 and 11) as well as CL weight (Fig. 
9) at 24 h indicated that BQ-610 did not prevent luteolysis in 90% (9/10) of the treated ewes. 
Because control ewes had an average of 1.7 ± 0.5 and 1.8 ± 0.4 CL in 6-h and 24-h groups, 
respectively, compared to only one CL in the treated ewes, data were presented as changes in 
concentrations of P4 with respect to h 0. Accordingly, at 6 h, serum P4 had declined equally in 
all groups of ewes with respect to h 0. In contrast, P4 concentrations decreased to sub-luteal 
values by 24 h in both groups of PGF2 -treated ewes, while in control animals P4 
concentrations rose more than 0.5 ng/ml with respect to h 0. Similarly, luteal P4 in the 24-h 
group was significantly lower in both groups of PGF2 -treated ewes than in control ewes. In 
contrast to the present results, Doerr et al. (2008) reported that blocking ENDRA with BQ-610, 
using a similar experimental approach, effectively reversed the decrease in concentrations of P4 
induced by exogenous PGF2  in all of 6 treated animals. In that study, P4 concentration in BQ-
610-treated ewes decreased rapidly after a luteolytic dose of PGF2 , and remained below 1 
ng/ml until hour 12 after PGF2 , but increased thereafter, reaching similar concentrations to the 
saline-injected ewes, around 48 h after PGF2 . Thus, it was suggested that during the first 12 h, 
PGF2  exerted its antisteroidogenic actions independent of mediation by END1, whereas in 
later stages END1 was required to suppress P4 production (Doerr et al., 2008). Nevertheless, 
only one ewe had a similar pattern of P4 secretion at 24 h in this study. In that animal, luteal 
concentration of P4 was 12.8 g/g, an amount considerably greater than mean luteal P4 in 





expression in this responsive BQ-610-treated animal was similar to the control ewes. Hence, 
the physiological response to the antagonist in the responsive BQ-610-treated animal indicated 
that luteolysis was prevented and the functional status of the CL was like a saline-injected ewe.  
Although CL weight did not differ among treatments at 6 h after PGF2 , luteal content of P4 
was significantly lower in both groups of PGF2 -treated ewes with respect to control animals. 
Consistent with the present findings, neither luteal volume nor CL weight decreased after 4 h of 
PGF2 -induced luteolysis in mid-cycle bovine CL, whereas serum and luteal P4 concentrations 
were significantly lower than in saline-injected cows (Tsai et al., 1998b). Judged by CL weight, 
it seems that at least 24 h are required for PGF2  to induce structural changes in the luteal tissue 
(Juengel et al., 1996; Tsai et al., 1998a). The first hours after PGF2  initiates luteal regression 
are associated with rapid decreases of circulating concentrations of P4, concomitant with the 
reduction of the luteal blood flow (Niswender et al., 1996; Wanatabe et al., 2006). 
Nevertheless, a transient increase in blood flow was associated with PGF2 -stimulated release 
of NO from vascular tissue (Acosta et al., 2002, 2008).  
Loss of steroidogenic capacity occurs mostly by down regulation of enzymes and proteins 
involved in P4 synthesis (Juengel et al., 1995; Tsai and Wiltbank, 1998; Tsai et al., 2001). It is 
likely that PGF2  reduced synthesis of P4 and transport of cholesterol, because both StAR and 
3 HSD were reduced equally by 6 h after PGF2 . However, as judged by the increment in the 
expression of 20 HSD at 24 h, metabolism of P4 may have contributed to decrease circulating 
and luteal concentrations of P4. Interestingly, treatment with BQ-610 upregulated even more 





shown by concentrations of serum P4. Moreover, as indicated by luteal P4 and weight and some 
other genes, the degree of luteolysis in BQ-610-treated ewes appeared to be greater than in 
vehicle-treated animals. In bovine luteal tissue, mRNA expression for StAR and 3 HSD 
decreased as early as 4 h after exogenous PGF2  (Tsai et al., 2001). Six hours after PGF2  is 
likely too early to determine if BQ-610 was able or not to effectively prevent luteolysis. During 
this early period, antisteroidogenic actions of PGF2  were independent of END1, as indicated 
by the profile of P4 concentration in BQ-610-treated ewes reported by Doerr et al. (2008). Even 
if structural luteolytic changes were induced by lower doses of PGF2 , (3 mg PGF2a/60 kg 
body weight) removal of luteolytic stimulus allowed increased serum P4 concentrations and 
reversed the effects of PGF2  in luteal tissue (Juengel et al., 2000).  
Apart from 3 HSD and StAR, other genes that promote luteal function, VEGF and TIMP-1, 
were downregulated by PGF2  in both 6 and 24-h groups. VEGF, an angiogenic and potent 
mitogenic growth factor, was highly expressed during early luteal development and 
downregulated at the end of the luteal phase (Schams and Berisha, 2004; Ribeiro et al., 2006; 
2007). In agreement with these data, studies in ruminants indicated a reduction of VEGF 
mRNA within 8 to 12 after exogenous PGF2 . (Neuvians et al., 2004b; Vonnahme et al., 2006). 
TIMP family members are associated with the maintenance of the ECM stability by reducing 
activity of MMP (Smith et al., 2002). TIMP-1 mRNA expression in ovine CL decreased 1 h 
after PGF2 , increased by 4 and 6 h, and decreased again from 12 through 48 h of PGF2 -
induced luteolysis (Ricke et al., 2002); and as occurred in this study, TIMP-2 remained 
unchanged from 6 through 48 h after PGF2  (Ricke et al., 2002a). In the light of this finding, it 





required in order for structural changes to take place. In this experiment, only MMP-14 was 
upregulated by PGF2 , and its expression increased from 6 to 24 h in all groups. In contrast, 
MMP-2 was similar among treatments and declined over time. In ovine luteal tissue, MMP-2 
transcript varied throughout the examined time after PGF2  with peaks of expression at 6 and 
24 h (Ricke et al., 2002b); whereas MMP-14 was upregulated by PGF2  as early as 6 h and 
remained unchanged over time. The lower expression of MMP-2 at 24 h than at 6 h in this 
study might be associated with fluctuation of this gene as reported by Ricke et al. (2002b). 
Once the antiluteolytic effect of P4 is withdrawn, PGF2  stimulates upregulation of factors 
involving in degradation of cellular matrix (Smith et al., 2002). In the current study, 
upregulation of MMP-14 is consistent with that concept, and with reports in ewes and cows that 
monitored expression of this transcript during a period of time after PGF2 -induced luteolysis 
(Ricke et al., 2002b; Kliem et al., 2007). 
In general, the expression pattern of genes that stimulate synthesis of P4 or inhibit its 
metabolism tended to favor luteal function in control ewes, but not in the BQ-610-treated group 
in which the ENDRA antagonist was expected to prevent luteolysis and maintain the functional 
status of the CL, as reported elsewhere for PGF2 -treated ewes (Doerr et al., 2008) and seen in 
spontaneous luteolysis (experiment 3). Moreover, BQ-610 appeared to promote the expression 
of genes related with structural luteolysis, because at 24 h after PGF2 , expression of caspases 3 
and caspases 8 were significantly greater in BQ-610-treated ewes than in vehicle-treated or 
control ewes (Fig 16). Moreover, Bcl-2/Bax ratio decreased over time only in the BQ-610-
treated group. These factors are involved in apoptosis and are upregulated within a few hours 





demise of the CL, and occurs as a consequence of degradation of luteal cellular and structural 
components (Hoyer, 1998; Pate and Keyes, 2001; Smith et al., 2002; Stocco et al., 2007). 
Upregulation of factors related with apoptosis, as shown for caspase 3 and 8 in this study, is an 
integral part of luteolysis and follows functional demise of the CL.  
A reasonable explanation why in this experiment BQ-610 treatment was ineffective to 
inhibit the luteolytic actions of END1 in PGF2 -induced luteolysis in the majority of the 
animals is not readily available. The experimental design of the current study was based on the 
findings reported by Doerr et al. (2008). Because concentrations of luteal P4 were ~ 42% lower 
in BQ-610/BQ-788-treated ewes (1 mg each) and approximately 26% lower in BQ-610-treated 
ewes (2 mg) than in saline-injected animals (Doerr et al., 2008), it was evident that BQ-610 
treatment in that concentration was not able to completely reverse the antisteroidogenic effects 
of PGF2  mediated by END1. Therefore, on the basis of that finding, the amount of BQ-610 
used in this study was increased from 2 to 2.5 mg/pump and the vehicle in which the antagonist 
was totally solubilized was 1 to 2 saline/methanol. The proportion of methanol in the BQ-610 
solution was considerably greater than (2.5 times) that reported by Doerr et al. (2008; 3 to 1 
saline/methanol). As described in material and methods, in a few cases, technical problems 
derived from catheter deattachment, presence of partial clots into the catheter or in the tissue 
around the end of the catheter might have interfered with the delivery of the BQ-610 or vehicle 
solution into the luteal tissue. At the moment of CL collection, 4 catheters (2 from 6-h vehicle, 
1 from 6-h BQ-610 and 1 from 24-h BQ-610) were not attached to the treated CL. It was 





necropsy was probably the cause. In addition, in 6 ewes (2 in 6-h vehicle, 2 in 6-h BQ-610 and 
2 in 24-h BQ-610) the end of the catheter attached to the treated CL was partially clotted. 
Was the increased volume of methanol in the BQ-610 solution the cause of the 
ineffectiveness of BQ-610 treatment to reverse the luteolytic effect of PGF2  mediated by 
END1? Perhaps so, if only the data from serum and luteal P4 and CL weight are considered. 
One can speculate that methanol, in that elevated concentration, was cytotoxic and supported 
induction of luteal regression. Another possible mechanism is that methanol interfered with or 
prevented binding of BQ-610 to ENDRA, and thus, luteal regression was a consequence of 
exogenous PGF2 . Nevertheless, if either of the previous mechanisms caused or allowed luteal 
regression in BQ-610-treated ewes, the effects on gene expression in BQ-610-treated ewes 
should have been similar (as were the serum and luteal P4 and CL weight) to those in vehicle-
treated animals. However, that was not the case, particularly in the 24-h group in which the 
genes related with apoptosis were upregulated more in BQ-610-treated than in vehicle-treated 
ewes after PGF2 . So, it seems that instead of preventing luteolysis by acting as an antagonist, 
the greater dosage of BQ-610 synergized with or enhanced the effect of PGF2 ; or alternatively, 
elevated concentrations of methanol may have modified the molecular structure of BQ-610 
making it able to activate ENDRA, because the expression of 20 HSD, caspase 3 and caspase 
8 in BQ-610-treated ewes at 24 h, was considerably greater than in vehicle treated ewes. The 
ratio Bcl-2/Bax in BQ-610-treated ewes changed from 2.29 in 6-h group to 0.79 in 24-h group; 
and tended to be lower only in BQ-610-treated with respect to control ewes. Moreover, at 24 h 





control animals; and reduction of CL mass is a reliable evidence of the cellular and structural 
changes during luteolysis (Stocco et al., 2007).  
From the previous argument a new question arises. Why did this hypothetical luteolytic 
effect attributed to BQ-610 not occur in all animals of this experiment and experiment 3 or in 
any animal of the Doerr et al. (2008) study? As mentioned earlier, in one ewe from this 
experiment and in 3 from experiment 3, the evidence indicated that BQ-610 effectively 
inhibited luteolysis. So, a combination of factors, including the presumptive ability of BQ-610 
to act as an agonist, the greater amount of methanol in the BQ-610 solution and some other 
factor derived from particular characteristics of the animals may explain this physiological 
incongruence? One or more of these possibilities may be a reasonable physiological 
explanation.   
Binding of END1 to type A G-protein coupled receptor activates at least three classes of G  
proteins (G q, G s, G i), each of them associated to a different signaling pathway (Aramori 
and Nakanishi, 1992; Wang et al., 1992; Ono et al., 1994; Takigawa et al., 1995). Different 
domains of the ENDRA structure are required for coupling to distinct G  proteins (Nussdorfer 
et al., 1999). In addition, there are at least two separable ligand interaction subdomains within 
the ENDRA (Sakamoto et al., 1993); and ENDRA gene can give rise to at least three transcripts 
by alternative RNA splicing (Miyamoto et al., 1996). Moreover, a single amino acid 
substitution altered the three-dimensional structure of the ligand-binding domain of ENDRA 
and significantly reduced the END1 binding activity (Juan, 2008). This complex molecular 
scenario in combination with the experimental conditions mentioned above, might make it 





conducive to luteal regression. To support this interpretation, it was documented that 
abosentan, a selective non-peptide ENDRA antagonist, stimulated p38 mitogen-activated 
protein kinase (MAPK/ERK) phosphorylation mediated by ENDRA in mouse cardiac tissue 
(Marchant et al., 2009). The ERK signaling pathway stimulated mRNA and protein expression 
of early growth response 1 (EGR1), and during PGF2 -induced luteal regression in the cow 
ERG1 induced expression of TGF 1, an important tissue remodeling protein also involved in 
apoptosis (Hou et al., 2008). 
Intraluteal injections of ENDRA antagonists in cows did not prevent antisteroidogenic 
effects of PGF2  mediated by END1 (Watanabe et al., 2006; Keator et al., 2008) or did not 
reverse completely the luteolytic effect of PGF2  in sheep (Hinckley and Milvae, 2001). As 
reported by Watanabe et al. (2006), administration of 5 intraluteal injections of LU-13522 (an 
ENDRA antagonist) at 2 h intervals in cows did not prevent the decrease in plasma P4 
concentration and the downregulation of mRNA for StAR and 3 HDS in response to a 
luteolytic dosage of PGF2 , as occurred in the vehicle-treated group. In addition, blockade of 
ENDRA upregulated expression of ppEND1 and ENDRB but did not affect ENDRA transcript 
expression (Watanabe et al., 2006).  
Administration of ENDRA antagonist by multiple intraluteal injections, delayed for about 2 
d the decrease of CL volume and blood flow in the area adjacent to the CL compared with 
vehicle-treated cows (Watanabe et al., 2006). The vasocontractive properties of END1 have 
been previously reported (Clarke et al., 1989; Ivi et al., 1994; Skovgaard et al., 2008), and the 





demise (Wise et al., 1982). Likewise, reduced blood flow implies lower concentrations of 
oxygen in the tissues, and hypoxic conditions in the bovine CL decreased P4 production 
(Nishimura et al., 2006) and induced apoptosis by upregulating  pro-apoptotic factors such as 
caspase 3 and BNIP3 (Nishimura et al., 2008).  
Interestingly, caspase 3 mRNA expression was significantly greater in vehicle-treated than 
antagonist-treated cows at 24 h after PGF2  (Watanabe et al., 2006), indicating that the role of 
END1 during luteolysis may be associated with structural rather than functional luteolysis. This 
hypothesis is supported by the findings reported by Doerr et al., (2008) that the early 
antisteroidogenic actions of PGF2  were independent of mediation by END1, whereas in later 
stages of luteolysis END1 was required to effectively induce demise of the CL. In experiment 
3, the delay of endogenous luteolysis for more than 5 days in 3 of 12 ewes by blocking 
ENDRA did not prevent the upregulation of genes related with apoptosis and structural 
luteolysis. Apparently, the elevated concentrations of P4 in the responsive BQ-610-treated 
animals exerted a protective effect, most likely by reducing the activity of apoptotic proteins. 
The protective and antiapoptotic effect of P4 on luteal function has been widely documented 
(Rueda et al., 2000; Goyeneche et al., 2003; Okuda et al., 2004; Nishimura et al., 2008). The 
assumption that in this experiment BQ-610 activated ENDRA and upregulated apoptosis-
related genes fits with the concept that actions of END1 during luteolysis are directly 
(inhibiting P4 production and stimulating apoptosis) and indirectly (via reduction of luteal 
blood flow) associated to structural luteolysis (Watanabe et al., 2006; Doerr et al., 2008; 





In conclusion, data from serum and luteal P4 and CL weight indicated that PGF2  induced 
luteolysis in both vehicle-treated and BQ-610-treated ewes. The pattern of gene expression 
further confirmed the luteolytic effect of PGF2  in both treated groups. But, interestingly, 
upregulation of genes related to apoptosis and structural luteolysis was greater in BQ-610-
treated than vehicle-treated ewes, indicating that instead of blocking actions of endogenous 
END1, BQ-610 might have stimulated actions ascribed to stimulation of ENDRA by END1 
(Watanabe et al., 2006; Doerr et al., 2008). This unexpected finding indicates that BQ-610 or 
its combination with a greater concentration of methanol may have activated ENDRA and 
therefore, induced over expression of these apoptotic factors. If so, these findings would 
confirm that END1 via ENDRA in luteal cells is associated with structural luteolysis as 
previously reported (Watanabe et al., 2006; Doerr et al., 2008). 
Experiment 3: Effect of chronic administration of an endothelin receptor 
type A antagonist on length of estrous cycle and functional characteristics of 
the corpus luteum during spontaneous luteolysis in sheep  
Materials and methods 
General experimental procedure 
Twenty one nonpregnant Suffolk ewes with at least one previous estrous cycle of normal 
length (15 to 19 days) were used in the experiment, conducted in winter (January-February) 
and fall (September-November) of 2008 with ewes from the West Virginia University research 





bearing a harness with a crayon in the area of the brisket; standing estrus was confirmed by 
teasing with another vasectomized ram. On day 9 of the estrous cycle (standing estrus = day 0) 
ewes were assigned randomly to receive one of the following treatments: Alzet® mini-osmotic 
pump (model 2002; Durect Corporation, Cupertino, CA) loaded with either vehicle (200 L 2:1 
methanol:saline solution; n = 9), or 2.5 mg of END receptor A antagonist (n = 12), BQ-610 
(Azepane-1-carbonyl-leu-D-Trp(For)-D-Trp-OH), diluted in  200 L of vehicle. The Alzet® 
mini-osmotic pumps (Bachem Bioscience Inc, King of Prussia, PA) designed to deliver 0.52 ± 
0.02 L/h for approximately 14 days, were kept overnight in sterile 0.9% saline solution at 
37 C previous to implantation in the ovary. Thus, the expected delivered dosage was 6.25 g/h 
of BQ-610. 
Minipumps were implanted surgically as described in experiment 2. Twenty four h after 
surgery, ewes were penned with a vasectomized ram bearing a harness with a crayon in the area 
of the brisket, and estrous detection was performed as described above. Blood samples were 
collected (8 ml) by jugular venipuncture at 6 h intervals from day 11 until estrus or until day 21 
of the estrous cycle in ewes that did not return to estrus. Blood samples were refrigerated for 24 
h to allow them to clot, and then centrifuged for 20 minutes at 2500 rpm. Serum was collected 
and kept at -20° C until radioimmunoassay for P4. Approximately 12 h after estrous detection 
or in the afternoon of day 21, ewes were euthanized, the correct position of the pumps and 
catheters were verified, and ovaries were collected. All animal procedures were approved by 






Luteal tissue processing 
Ovaries were refrigerated in ice-cold PBS, transported to the lab within 2 to 3 h after 
surgery, and each CL was dissected, weighed, sectioned into 5 pieces that were weighed 
individually and 3 of them were frozen in liquid nitrogen and stored at -80°C. One piece of 
each CL was homogenized in PBS (1 ml/100 mg of tissue), centrifuged, and supernatant stored 
at -20 °C, for determination of luteal P4. A second fragment was placed in Bouin’s fixative for 
at least 24 h, and processed later to assess cellular morphology and apoptosis.  
Bouin’s fixative was removed by rinsing luteal tissue successively in 70% alcohol. Pieces of 
tissue were embedded in paraffin and cut into 10 μm sections, then mounted about 8 to 14 
sections on each microscope slide. After deparaffinization with xylene and rehydration through 
descending grades of alcohol, tissue specimens were stained with the terminal deoxynucleotide 
transferase-mediated deoxy-UTP nick labeling method (TUNEL) for detection of apoptotic 
cells by immunohistochemistry (APO-BRDU-IHC; Phoenix Flow Systems, San Diego, CA). 
Briefly, the procedure was performed as follows: (1) permeabilization of specimen with 
proteinase K (20 min at room temperature); (2) inactivation of endogenous peroxidases with 
30% H2O2 diluted 1:10 in methanol (5 min at room temperature); (3) equilibration reaction with 
1X reaction buffer followed by a labeling reaction in humid chamber (at 37 C for 90 min) 
using bromolated deoxyuridine triphosphate nucleotides (Br-dUTP) and the enzyme terminal 
deoxynucleotidyl transferase (TdT); in the next reaction (4) an anti-BrdU antibody directly 
conjugated to biotin was attached to the Br-dUTP’s (in darkness, for 1-1.5 hours at room 
temperature) followed  by (5) the attachment of peroxidase-conjugated avidin to the biotin 





incorporated Br-dUTP’s. Slides were observed under an Olympus PROVIS AX70 microscope 
to identify specific brown color in the cellular nuclei indicative of apoptosis. Three fields-of-
view from two different sections, at least 100 μm apart, were evaluated to quantify the number 
of apoptotic cells, and to estimate the rate of apoptosis for each treatment. 
Assessing gene expression  
To corroborate the functional status of the CL, expression of genes involved in progesterone 
production or structural luteolysis was determined by quantitative RT-PCR, applying a 
transverse-transcription real-time PCR procedure identical to that described in experiment 2. In 
addition to tissue from BQ-610 and vehicle ewes, luteal tissue from control ewes (no 
minipump; saline injection; day 10-11 of estrous cycle) obtained in experiment 2 was used. 
Accession number, sequence, animal source and additional characteristics of each gene primer 
are indicated in Table 5. 
Radioimmunoassays for progesterone 
Concentrations of P4 in serum and luteal tissue were measured in duplicate by RIA as 
previously described (Sheffel et al., 1982). Assay sensitivity averaged 0.18 ng/ml, and inter- 
and intraassay coefficients of variation were 9.5% and 9.8%, respectively. 
Statistical Analysis 
Differences in concentrations of serum and luteal P4, luteal weight, length of estrous cycle, 
cellular apoptosis and gene expression among treatments were evaluated by one-way analysis 





NC). Differences among means were compared by the LSM procedure of SAS. Data were 
expressed as mean ± SEM. Proportions of ewes in which the length of the estrous cycle was 
prolonged beyond 20 d were analyzed by Chi-square method of SAS. 






















StAR NM_001009243 O. aries F: 5’-TGCTGAGTAAAGTGATCCCTGA-3’ 
R: 5’-AGGACCTTGATCTCCTTGACAC-3’ 
148 60 -3.631 
3 HSD NM_174343 B. taurus F: 5’-CCACACCAAAGCTACGATGA-3’ 
R: 3’-TGTAAATTGGACTGAGCAGGAA-3’ 
148 60 -3.419 
PPEND1 NM_001009810 O. aries F: 5’-TCTGCAAGTTGTTCCCCTTT-3’ 
R: 3’-ATCTCAATGGCTGTGACCAAC-3’ 
148 60 -3.331 
ENDAR NM_001009433 O. aries F: 5’-TCTGCAAGTTGTTCCCCTTT-3’ 
R: 3’-ATCTCAATGGCTGTGACCAAC-3’ 
148 60 -3.208 
Bcl-2 DQ152929 O. aries F: 5’-TGGATGACCGAGTACCTGAA-3’ 
R: 3’-CAGCCAGGAGAAATCAAACAG-3’ 
120 60 -3.314 
Bax AF163774 O. aries F: 5’-GAAGCGCATTGGAGATGAA-3’ 
R: 3’-AAGTAGAAAAGGGCGACAACC-3’ 
159 60 -3.286 
Fas-R NM_001123003 O. aries F: 5’-CGGAAGAATGGTATGGAGGA-3’ 
R: 3’-TGCAAGAGCTTTTGGGAGAT-3’ 
162 60 -3.375 
Caspase 3 AF068837 O. aries F: 5’-GGATTATCCTGAAATGGGTTTATG-3’ 
R: 3’-GATCGTTTTTAATCCTGACTTCGT-3’ 
155 60 -3.266 
TIMP-1 NM_001009319 O. aries F: 5’-CCAGACATCCGATTCATCTACA-3’ 
R: 3’-GCAGAACTCATGCTGTTCCA-3’ 
167 60 -3.558 
GAPDH AF030943 O. aries F: 5’-TCTCAAGGGCATTCTAGGCTAC-3’ 
R: 3’-TGTAGCCGAATTCATTGTCG-3’ 










Length of the estrous cycle and corpus luteum morphology  
Three of 12 (25%) ewes treated with BQ-610 (in the successive named responsive BQ-610-
treated ewes) did not show estrus before d 21 compared to 0 of 9 (0%) vehicle-treated ewes (P 
= 0.33); the remaining nine BQ-610 ewes had cycles averaging 15.3 ± 0.2 d. Estrous cycles in 
the responsive BQ-610-treated ewes were at least 5.5 d longer than in vehicle-treated ewes (> 
21 d vs. 15.5 ± 0.2 d, respectively; P<0.0001). Differences in size, color and weight of the CL 
were important aspects to assess the effect of blocking ENDRA (Fig. 18 and 19) during 
spontaneous luteolysis in sheep. Corpora lutea from the three responsive BQ-treated ewes were 
approximately 1.6 times heavier and had 2.4 times more volume than CL from vehicle-treated 
ewes. In addition, CL from responsive BQ-610-treated ewes were pink while CL from control 
ewes had pallid color.  
Serum and luteal progesterone 
Serum concentrations of P4 in the three responsive BQ-610-treated ewes remained above 1.5 
ng/ml through d 21 of the cycle (P < 0.01). In this group, P4 concentration averaged 2.97 ± 0.08 
ng/ml from d 11 through d 16 and decreased to 1.91 ± 0.10 ng/ml from d 17 to d 21 of the cycle 
(P<0.0001). In non-responsive BQ-610-treated ewes, initial concentration of P4 was 1.75 ng/ml 
and decreased gradually to minimal values by d 15 of the estrous cycle. In vehicle-treated ewes, 
P4 concentration remained above 2 ng/ml from d 11 to d 13 and then decreased progressively 
until d 15 of the estrous cycle (Fig 20). Luteal content of P4 was 16 fold greater in responsive 






Luteal tissue in responsive BQ-610-treated ewes appeared normal with 53.3 ± 5.8% of 
apoptotic cells, whereas luteal tissue in vehicle-treated ewes was markedly disorganized and in 
an advanced stage of structural regression (Fig 22). In this tissue it was not possible to detect 
apoptotic cells. 
Gene expression 
To examine functional status of the CL, expression of genes involved in progesterone 
production or structural luteolysis was determined in ewes treated with BQ-610 or vehicle and 
in mid-phase CL (n = 3 per group; Table 6). Although StAR mRNA expression was about 3 to 
5 times greater in mid-phase CL and responsive BQ-610-treated ewes than in vehicle-treated 
ewes, differences were not significant. Also, luteal tissue from responsive BQ-610-treated ewes 
and mid-phase CL had greater expression of transcript for 3 HSD and TIMP-1 than vehicle-
treated group. In regressed CL, both ppEND1 and ENDRA mRNA expression were greater (P 
≤ 0.05) than mid-phase CL or responsive BQ-610-treated CL. The expression of Bcl-2 was not 
affected by treatments; nevertheless, it was 3.9 and 1.7 times greater in mid-phase CL than in 
CL from responsive BQ-610-treated or vehicle-treated ewes, respectively. Bax mRNA 
expression was significantly lower in responsive BQ-610-treated and mid-phase CL than in the 
vehicle-treated group. The Bcl-2:Bax ratios were 2.25, 0.69 and 0.64 for mid-phase CL, 
responsive BQ-610-treated and vehicle-treated ewes, respectively (P > 0.05). There was no 
significant effect of treatment on the expression of Fas-R. In contrast, mid-phase CL had lower 

















Figure 18. Representative picture of macroscopic characteristics of corpora lutea collected 12 h 
after onset of estrus in vehicle-treated ewes, or on the afternoon of d 21 in BQ-610-treated 

















Figure 19. Effect of chronic administration of either BQ-610 (n = 3) or vehicle (n = 9) during 
spontaneous luteolysis on corpus luteum weight in sheep. Bars represent mean weight (g) ± 
SEM of corpora lutea collected 12 h after onset of estrus in vehicle-treated ewes, or on the 







































Figure 20. Effect of chronic administration of either BQ-610 or vehicle during spontaneous 
luteolysis on serum concentrations of progesterone in sheep. Blood samples were collected by 
jugular venipuncture at 6 h intervals from d 11 until estrus or until d 21 of the estrous cycle in 
ewes that did not return to estrus. Data points represent mean (± SEM) serum progesterone 
(ng/ml) per time of sampling for responsive BQ-610-treated (n = 3; ○), non-responsive BQ-
610-treated (n = 9; ▲) and vehicle-treatted (n = 9; ■) ewes. Values are statistically different 















Figure 21. Effect of chronic administration of either BQ-610 (n = 3) or vehicle (n = 9) during 
expected spontaneous luteolysis on luteal content of progesterone in sheep. Bars represent 
mean (± SEM) concentrations ( g/g) of progesterone in homogenized corpus luteum extracts. 
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Figure 22. Representative examples of cellular morphology and apoptosis in luteal tissue after 
chronic administration of either (A) BQ-610 (n = 3) or vehicle (n = 9) during spontaneous 
luteolysis in sheep. In responsive BQ-610-treated ewes luteal tissue appeared normal with 53.3 
± 5.8% of apoptotic cells, whereas it was markedly disorganized and in an advanced stage of 
structural regression in vehicle-treated ewes.  
 
 
Table 6. Effect of chronic administration of either BQ-610 or vehicle during expected 
spontaneous luteolysis on expression of genes involved in progesterone production or structural 




Treatments  Level of 
significance 
Mid-phase CL BQ-610 Vehicle 
StAR 1.80 ± 1.15 
a
 2.49 ± 1.15 
a
 0.47 ± 1.15 
a
      P > 0.05 
3 HSD 0.55 ± 0.08 
a
 1.22 ± 0.08 
b




P < 0.01 
TIMP-1 1.06 ± 0.11 
a
 0.81 ± 0.11 
a
 0.28 ± 0.11 
b
 
   a,b 
P < 0.01 
ppEND1 0.69 ± 0.27 
a,b
 0.97 ± 0.27 
b
 1.96 ± 0.27 
c
 
   a,c 
P < 0.04; 
b,c 
P < 0.01 
ENDRA 0.40 ± 0.39 
a
 0.56 ± 0.39 
a
 3.24 ± 0.48 
b
 
   a,b 
P < 0.01 
Bcl-2 2.90 ± 0.86 
a
 0.76 ± 0.86 
a
 1.67 ± 1.48 
a
      P > 0.05 
Bax 1.29 ± 0.23 
a
 1.26 ± 0.23 
a
 2.61 ± 0.30 
b
 
   a,b 
P < 0.02 
Fas-R 0.77 ± 0.18 
a
 1.16 ± 0.18 
a
 0.95 ± 0.32 
a
      P > 0.05 
Caspase 3 1.47 ± 0.53 
a
 3.16 ± 0.53 
b,c




P < 0.08; 
a,c 
P < 0.04 






In this study, blocking of ENDRA prevented endogenous luteolysis for more than 5 days in 
only 25% of 12 BQ-treated ewes, compared with none of the 9 ewes treated with vehicle. Data 
on macroscopic characteristics of the CL, serum and luteal concentration of P4 and gene 
expression supported this observation, and confirmed previously published in vivo studies in 
ruminants about the role of END1 in mediating luteolytic actions of PGF2  (Hinckley and 
Milvae, 2001; Doerr et al., 2008; Keator et al., 2008). Although intraluteal injection of BQ-123 
(an ENDRA antagonist) did not reverse completely the luteolytic effect of PGF2 , 
intramuscular injection of both END1 (100 g) and PGF2  (7.5 mg) effectively reduced P4 
concentrations by 48 h post-treatment, and shortened the length of the cycle (Hinckley and 
Milvae, 2001).  
A large body of evidence indicates that END1, a 21-amino acid peptide that regulates 
vascular function in different tissues, participates in the luteolytic cascade initiated by uterine 
PGF2  at the end of the luteal phase. In ruminants, a greater ppEND1 and ENDRA mRNA 
expression was observed at the end of estrous cycle near the time of luteolysis (Mamluk et al., 
1999; Girsh et al., 1996b) and after exogenous PGF2  during mid-luteal phase (Levy et al., 
2000; Hinckley and Milvae, 2001; Choudhary et al., 2004). In addition, END1 reduced both 
basal and LH-stimulated production of P4 and this anti-steroidogenic effect was reversed by the 
addition of a selective ENDRA antagonist (Girsh et al., 1996a; Hinckley and Milvae, 2001; 
Doerr et al., 2008). In concordance with the previous reports, expression of ppEND1 and 





and responsive BQ-treated CL, which further supports the relevance of the END system in 
mediating luteal regression in ruminants. 
Different methods for administration or delivery of ENDRA antagonists in vivo have been 
applied to test the role of END1 in luteal regression. Apparently, intraluteal injection of a 
selective ENDRA antagonist (BQ-610 or LU-13522) was ineffective to reverse the decline of 
P4 production induced by PGF2  in cows (Watanabe et al., 2006; Keator et al., 2008). In 
contrast, intrauterine infusions of 500 g of BQ-610 every 12 h from d 16 through 18 of the 
estrous cycle delayed spontaneous luteolysis in heifers for about 2 days. Moreover, BQ-610 
chronically delivered into the CL by means of an osmotic mini-pump effectively reversed the 
luteolytic effect of PGF2  12 h after its administration, allowing concentrations of  serum P4 
attain similar values to the control group by 48 h after PGF2  (Doerr et al., 2008). Apparently, a 
direct action of PGF2  decreased serum P4 during early luteolysis, whereas END1 was required 
in later stages, indicating that END1 might participate in structural more than functional 
luteolysis. 
This study followed the same experimental approach utilized by Doerr et al. (2008), but the 
greater dosage of BQ-610 prevented spontaneous luteolysis and lengthened the estrous cycle in 
only 3 of 12 (25%) ewes. Endogenous PGF2  starts to be secreted from the uterus in increased 
amounts around day 11 to 13 of the sheep estrous cycle (Silvia et al., 1984; Zarco et al. 1988b). 
The sustained delivery of BQ-610 for more than 8 days after the beginning of endogenous 





Different methods to assess the functional features in luteal tissue treated with BQ-610 or 
vehicle were used in this experiment: macroscopic and histological characteristic, steroidogenic 
capacity and expression of genes related to P4 synthesis and structural luteolysis. Thus, data 
from this experiment evaluated both functional and structural aspects of luteolysis.  
Functional regression of the CL is characterized by a rapid decrease of P4 production by 
luteal steroidogenic cells coincident with a transient increased followed by a diminution of 
blood flow to the CL (Niswender et al., 1975; Nett et al., 1976). During this short period 
synthesis and secretion of P4 is inhibited, mostly by interrupting mobilization of cholesterol 
throughout the cytoplasm and outer mitochondrial membrane (Murdoch, 1996; Juengel et al., 
2000; Tsai et al., 2001). Thus, lacking the substrate to synthesize P4, steroidogenic enzyme 
activity declines and less P4 is secreted by large and small luteal cells. Although differences in 
mRNA expression for StAR were not significant, probably due to the large variation among 
samples (and few samples per treatment), values from responsive BQ-610 and mid-cycle CL 
were 5.3 and 3.8 times greater than in CL of vehicle-treated ewes. Transcript concentration for 
3 HSD was greater in responsive BQ-treated and mid-cycle CL than in vehicle-treated CL. 
Hence, there were greater serum and luteal concentrations of P4 in responsive BQ-610-treated 
ewes. These data, together with similar expression values for StAR and 3 HDS transcripts in 
mid-cycle CL and responsive BQ-610-treated CL, strongly indicate the cellular metabolic 
machinery to synthesize P4 by luteal steroidogenic cells was completely operative in responsive 
BQ-610-treated ewes at day 21 of the estrous cycle.  
In vehicle-treated ewes, luteal weight 12 h after estrus was 0.39 ± 0.03 g, about 37% lighter 





Moreover, judged by color, CL from the three responsive BQ-610-treated ewes were larger and 
appeared healthier than those collected from vehicle-treated ewes.  As seen by Braden et al. 
(1988), Juengel et al. (1996) and Tsai et al. (1998a), CL weight significantly decreased 30 to 
50% by 24 to 36 h after exogenous PGF2  in sheep. The decrease in CL weight represents clear 
evidence that luteal regression has been already induced and implies death and phagocytosis of 
cellular components, mostly endothelial and steroidogenic luteal cells, and degradation of 
cellular matrix as well (Braden et al., 1988; Sawyer et al., 1990; Pate and Keyes, 2001; Smith et 
al., 2002). However, morphological alterations were not evident until 24 to 36 h after initial 
exposure to PGF2  (Sawyer et al., 1990).  
The expression pattern of genes related with structural luteolysis appeared to be less clear. 
Although the expression of Bax mRNA was significantly lower in BQ-610 and mid-cycle CL 
compared with vehicle CL, Bcl-2 and Fas-R expression did not differ among treatments. 
Moreover, the ratio between Bcl-2 and Bax mRNA was around 3.5 times greater in mid-cycle 
CL than in CL of either responsive BQ-610-treated or vehicle-treated ewes. Bcl-2 and Bax are 
proteins that prevent and promote apoptosis, respectively, and their relative abundance at a 
specific luteal stage could favor or oppose apoptosis (Tilly et al., 1996). While Bcl-2 prevents 
apoptosis by regulating mechanisms related to Ca
2+
 homeostasis and oxidative stress (Kane et 
al., 1993; Pinton et al., 2001), Bax promotes apoptosis by antagonizing anti-apoptotic actions of 
Bcl-2 (Nutt et al., 2002; Chami et al., 2004). Concentrations of Bax but not Bcl-2 mRNA and 
protein increased after PGF2 -induced luteolysis in ruminants (Rueda et al., 1997; Yadav et al., 
2005); this change was reflected in Bax/Bcl-2 ratio for both mRNA and protein that was 





addition, both protein and activity of caspases 3 and 9 increased after PGF2  (Yadav et al., 
2005). Thus, it is evident that PGF2  upregulates proteins that induce apoptosis in luteal cells. 
Interestingly, PGF2  significantly increased the expression of caspase 3 in vehicle-treated 
animals as well as in BQ-610-treated ewes compared with mid-cycle CL. This finding agrees 
with the fact that luteal tissue from the three responsive BQ-610-treated ewes had 53.3 ± 5.8% 
of apoptotic cells and that serum concentrations of P4 in this group were about 36% lower from 
day 16 through 21 of the cycle compared with the previous days. Nevertheless, luteal 
concentrations of P4 were elevated, indicating that CL from responsive BQ-610-treated ewes 
were completely active. To provide a physiological explanation for this discrepancy it is 
important to consider two aspects. First, BQ-610 blocks ENDRA but does not prevent PGF2  
from binding to its receptor. In pregnant ewes (Nett et al., 1976; Lewis et al., 1977; Vincent and 
Inskeep, 1986), secretion of uterine PGF2  around d 21 post estrus is still elevated to mid range, 
and consequently PGF2  may be inducing intracellular changes at mRNA or even protein levels 
by different pathways than END1 utilizes to mediate PGF2 -induced luteolysis. Second, anti-
apoptotic and protective effects of P4 on luteal function have been documented (Rueda et al., 
2000; Goyeneche et al., 2003; Okuda et al., 2004; Nishimura et al., 2008). Thus, elevated 
concentrations of P4 in BQ-610-treted ewes may counteract the luteolytic actions of PGF2  by 
inhibiting or reducing activity of pro-apoptotic factors. 
In summary, chronic delivery of BQ-610 into the CL during mid- to late-luteal phase 
prevented natural luteolysis and prolonged the estrous cycle for more than 5 days in only 3 of 





were similar to mid-phase CL. Overall this study indicates that END1 might plays mediatory 
role during spontaneous luteolysis in the ewe. 
General discussion 
Immediately after the LH surge, the pattern of steroid secretion from the preovulatory 
follicle in known to change abruptly (Murdoch and Dunn, 1982; Fortune and Hansel, 1985) 
from estrogen to P4 dominance. It was postulated that END1, a 21-amino acid peptide with 
recognized anti-steroidogenic properties, might modulate steroid production preventing 
premature luteinization of granulosal and thecal cells (Tedeschi et al., 1992; Flores, 2000). In 
experiment 1, the protocol designed for collection of large preovulatory follicles was successful 
and granulosal cells from 20 of 28 follicles were cultured and challenged to 10 different 
treatments, resultant from combinations of LH, END1, ENDRA and ENDRB. However, neither 
E2 nor P4 accumulation in the culture media was affected by treatments after 24 h of incubation. 
To interpret these findings, it is important consider three aspects. First, granulosal cells from 
large preovulatory follicles were exposed to greater concentrations of endogenous LH for 
several hours and thereafter to supplemented LH during in vitro incubation. Second, removing 
granulosal cells in this particular follicular developmental stage and culturing them in a serum 
free culture medium may have triggered their luteinization; as judged by greater concentrations 
of P4 than E2 in the culture media. Third, as occurs during luteolysis, END1 may act in 
conjunction with other locally produced ovarian mediators regulating follicular steroid 
production, and therefore, the absence of these factors in the culture media may have allowed 
luteinization of granulosal cells. Apparently, a more appropriate culture system would be 





preovulatory follicles in sheep. Alternatively, collection of preovulatory follicles earlier, and 
incorporation of FSH and serum in culture media, may allow elucidation of the role of END1 in 
modulating steroid production by granulosal cells prior to ovulation in sheep. In earlier in vitro 
studies, FSH-simulated P4 production by granulosal cells collected from small- and medium-
sized swine follicles was inhibited by END1 (Kamada et al., 1993; Flores et al., 1992; 1999). 
However, END1 also reduced production of LH-stimulated P4 by granulosal cells isolated from 
medium-sized follicles in pigs (Iwai et al., 1991). 
A large body of evidence indicates that END1 plays an important role in luteal regression 
(Girsh et al., 1996a; 1996b; Miyamoto et al., 1997; Ohtani et al., 1998; Hinckley and Milvae, 
2001; Doerr et al., 2008; Keator et al., 2008). In experiment 2, the role of END1 in structural 
luteolysis was not elucidated, as judged by concentrations of serum and luteal P4 and CL 
weight, as well as the over expression of the genes 3 -HSD and caspases 3 and 8 in BQ-610-
treated compared to vehicle-treated luteal tissue. Apparently, the increased rate of delivery of 
BQ-610 into the CL in combination with greater concentrations of methanol and individual 
animal features might have interfered with the binding ability or modified the molecular 
structure of BQ-610. Also, blockade of ENDRA by BQ-610 may have allowed END1 to bind 
ENDRB and trigger downstream signaling through this receptor contributing to an increase in 
the luteolytic signal. In the cow, ENDRB mRNA expression was greater at the end of luteal 
phase, during luteal regression (Berisha et al., 2002) and after an exogenous dose of PGF2  
(Schams et al., 2003; Watanabe et al., 2006) indicating a putative role of this receptor during 
luteolysis.   However, concentrations of ENDRB mRNA in luteal cells were minimal during 





PGF2  was reversed by blocking ENDRA but not ENDRB (Doerr et al., 2008) in the ovine CL. 
The ENDRB is more abundant in vascular endothelial cells and its activation by END1 
stimulated releases of NO (Ishiguro et al., 2001; Hirata et al., 1993), which is an important 
inhibitor of luteal P4 production. It was proposed that NO acts as a local mediator of PGF2 -
induced regression in bovine CL (Jaroszewski and Hansel, 2000; Jaroszewski et al., 2003). 
Thus, the greater availability of endogenous END1 during induced and spontaneous luteolysis 
in experiments 2 and 3, respectively, as well as the hypothetical increased concentrations of 
ENDRB at that time, may have induced direct and/or indirect luteolytic signals that caused over 
expression of pro-apoptotic factors in those animals in which luteolysis was not prevented.  
Under the experimental conditions described above, blockage of ENDRA in experiments 1 
and 2 prevented luteolysis in only 10 and 25% of the treated animals, compared to 100% in the 
earlier study by Doerr et al. (2008). Pharmacological dosage of PGF2  in experiment 1 versus 
physiological secretion of uterine PGF2  in experiment 2 may account for the 15 percentage 
point difference. In addition to the increased concentrations of methanol in the vehicle, 
placement of the catheter into the CL may have disrupted the functional capacity of the CL 
treated with BQ-610. Therefore, secretion of lower amounts of progesterone was unable to 
counteract the direct and indirect luteolytic actions of PGF2 ., and as a consequence, luteolysis 
was not prevented. Perhaps lower luteal damage and greater steroidogenic capacity of the CL in 
those BQ-610 responsive animals during natural luteolysis might explain why BQ-610 
effectively prevented luteolysis in 25% of the treated animals compared with only 10% of the 
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